Chimeric Antigen Receptor (CAR) T cell Immunotherapy- Competitive Landscape, Pipeline and Market Analysis, 2018

Chimeric Antigen Receptor (CAR) T cell Immunotherapy- Competitive Landscape, Pipeline and Market Analysis, 2018

  • Pages: 289
  • Geography: Global
  • Delivery Timeline: 24 Hours
  • Publication: Jul, 2018
  • SKU: DISR0005
  • Single User License
    (20% Off)
    $2,950.00
  • Site License
    (30% Off)
    $5,900.00
  • Global License
    (40% Off)
    $8,850.00
Request Sample

Name*  
Email ID*  
Mobile*  
Company*  
Country*  
Zip Code*  
Address*  
Message*  
X

Request Sample Pages

Request Before Buy
Name*  
Email ID*  
Mobile*  
Company*  
Message*  
X

Inquire Before Buy

Send Friend
Name*  
Email ID*  
Mobile*  
Company*  
Message*  
X

Send to Friend

"Chimeric Antigen Receptor (CAR) T cell Immunotherapy- Competitive Landscape, Pipeline and Market Analysis, 2018", report provides comprehensive Insight about marketed and pipeline drugs across this Immunotherapy. The report provides the detailed analysis of 190+ products along with 60+ companies involved. Celgene Corporation and bluebird bio has been granted Breakthrough Therapy Designation from FDA and Prime Eligibility from EMA for bb2121 Anti-BCMA CAR-T Cell Therapy for Relapsed and Refractory Multiple Myeloma.

Products covered by Phase

• Phase II, Phase I and IND 

• Pre-clinical and Discovery

Overview of pipeline development activities for Chimeric Antigen Receptor (CAR) T cell Immunotherapy
Pipeline analysis of 190+ therapeutic drugs include but are not limited to drug description and development activities focusing on clinical and non-clinical results, designations, collaborations & licensing deals, grants, technology and patent details. Report contains the development and sale activities for marketed drugs.
Therapeutic segmentation of products for Chimeric Antigen Receptor (CAR) T cell Immunotherapy
The report comprises of comparative pipeline therapeutics assessment by development stage, therapy type, molecule type, and administration route across this Immunotherapy. 

Methodology
Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. 
Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases. 

Scope 

• The report provides competitive pipeline landscape of Chimeric Antigen Receptor (CAR) T cell Immunotherapy

• The report provides the marketed drugs information including its sales, development activities and details of patent expiry

• The report provides the insight of current and future market for Chimeric Antigen Receptor (CAR) T cell Immunotherapy

• The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information

• Coverage of the Chimeric Antigen Receptor (CAR) T cell Immunotherapy pipeline on the basis of target, MOA, route of administration, technology involved and molecule type

• The report reviews key players involved in the therapeutics development for Chimeric Antigen Receptor (CAR) T cell Immunotherapy and also provide company profiling

• Pipeline products coverage based on various stages of development ranging from mid stage till discovery stages

• Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Reasons to Buy

• Identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage

• Establish a comprehensive understanding of the current pipeline scenario across Chimeric Antigen Receptor (CAR) T cell Immunotherapy to formulate effective R&D strategies

• Assess challenges and opportunities that influence Chimeric Antigen Receptor (CAR) T cell Immunotherapy R&D

• Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain

Competitive Advantage

• Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine

• Devise corrective measures for pipeline projects by understanding Chimeric Antigen Receptor (CAR) T cell Immunotherapy pipeline depth and focus of Indication therapeutics

• Developing strategic initiatives to support your drug development activities

• Devise in licensing and out licensing strategies by identifying prospective partners with progressing projects for Chimeric Antigen Receptor (CAR) T cell Immunotherapy to enhance and expand business potential and scope 

• Provides strategically significant competitor information, analysis, and Insight to formulate effective R&D development strategies

• Our extensive domain knowledge on therapy areas support the client in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive drugs

• Gaining a full picture of the Competitive Landscape for Evidence based Decisions

1. Report Introduction
2. Executive Summary Snapshot
3. Executive Summary
4. Introduction
4.1. Chimeric antigen receptor (CAR) T-cells
4.2. History
4.3. CARs and Generations
4.4. Advantages of CAR-T cells
4.5. Adverse Events with CAR T-cell Therapy
4.6. Limitations of Existing Technologies for CAR T-Cells
5. CAR-T Cell Therapy-Analysis
5.1. CAR-T Collaboration Deals
5.1.1. CAR-T Cells Therapy Collaborations and Deal Year
5.1.2. Collaborations & Deal Value Trends
5.1.3. Companies collaborations for future developments
5.2. CAR-T Acquisitions Deals
5.2.1. CAR-T Cells Therapy Acquisitions Trends
5.2.2. CAR-T Cells Therapy Acquisitions Offerings by Big Giants
5.3. New facilityfor the development of CAR-T cells
5.4. JCAR015: Major Set Back for Juno Therapeutics
5.5. CAR-T Licensing Opportunities
5.6. Pipeline Scenario
5.6.1. Pipeline Products under Development-An Overview
5.6.2. Pipeline Products under Development by Company
5.6.3. CAR T-cells Therapeutic Areas & Companies
5.6.4. CAR-T cells Targeted Antigens
5.7. Target: CD19, Related Drug Products, Phase & Company
5.7.1. CAR-T Therapies-Clinical trials & Completion Year
5.7.2. CAR T-cell Technologies & Companies Involved
5.7.3. CAR-T Safety Switches & Company involved
5.7.4. Companies with Upcoming CAR-T Therapeutics
6. Pipeline Profiles
6.1. Company A
6.1.1. Drug A: Company 1
Product Description
Research and Development
Clinical Studies
6.1.2. Drug B: Company 1
Product Description
Research and Development
Clinical Studies
6.2. Company B
6.2.1. Drug C: Company 2
Product Description
Research and Development
Clinical Studies
To be continued in report…
7. Upcoming Technologies Better than CARs
8. Market Drivers
9. Market Barriers
10. SWOT Analysis
11. Report Methodology
12. Consulting Services

Table 1: CARs Generations-Associated Target Antigens and Indications
Table 2: CAR-T Cells Therapy - Company Collaborations and Deal Year, 2017
Table 3: CAR-T Cells Therapy - University Collaborations and Deal Year, 2017
Table 4: CAR-T Cells Therapy collaboration Deals and Values, 2017
Table 5: Companies CAR-T Investment for future developments, 2017
Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2017
Table 7:Companies open for licensing and collaborations, 2017
Table 8:Number of Products under Development, 2017
Table 9:Number of Products under Development by Companies, 2017
Table 10:Number of Products under Development by Indication, 2017
Table 11:Number of Products Targeting CD19 Antigen, 2017
Table 12:Number of Products Targeting Other Antigens, 2017
Table 13: Number of CAR-T Ongoing Clinical Trials & Completion Year, 2017
Table 14:CAR T-cell Companies and Technologies, 2017

Figure 1: Companies Collaborations vs. Financial year, 2017
Figure 2: Number of Companies Collaborations, 2017
Figure 3: Collaborations and Upfront Deal Values (In million, $), 2017
Figure 4: Number of Products under Development, 2017
Figure 5: Number of Products under Development by Companies, 2017
Figure 6: Number of Products under Development by Indication, 2017
Figure 7: CAR-T cell Targeted Antigens (%), 2017
Figure 8: Number of Products Targeting CD19 antigen by Phase, 2017
Figure 9: Number of CAR-T Clinical Trials & Completion Year, 2017
Figure 10:CAR T-cell Companies and Technologies, 2017

Table 1: CARs Generations-Associated Target Antigens and Indications
Table 2: CAR-T Cells Therapy - Company Collaborations and Deal Year, 2017
Table 3: CAR-T Cells Therapy - University Collaborations and Deal Year, 2017
Table 4: CAR-T Cells Therapy collaboration Deals and Values, 2017
Table 5: Companies CAR-T Investment for future developments, 2017
Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2017
Table 7:Companies open for licensing and collaborations, 2017
Table 8:Number of Products under Development, 2017
Table 9:Number of Products under Development by Companies, 2017
Table 10:Number of Products under Development by Indication, 2017
Table 11:Number of Products Targeting CD19 Antigen, 2017
Table 12:Number of Products Targeting Other Antigens, 2017
Table 13: Number of CAR-T Ongoing Clinical Trials & Completion Year, 2017
Table 14:CAR T-cell Companies and Technologies, 2017

Figure 1: Companies Collaborations vs. Financial year, 2017
Figure 2: Number of Companies Collaborations, 2017
Figure 3: Collaborations and Upfront Deal Values (In million, $), 2017
Figure 4: Number of Products under Development, 2017
Figure 5: Number of Products under Development by Companies, 2017
Figure 6: Number of Products under Development by Indication, 2017
Figure 7: CAR-T cell Targeted Antigens (%), 2017
Figure 8: Number of Products Targeting CD19 antigen by Phase, 2017
Figure 9: Number of CAR-T Clinical Trials & Completion Year, 2017
Figure 10:CAR T-cell Companies and Technologies, 2017

Table 1: CARs Generations-Associated Target Antigens and Indications
Table 2: CAR-T Cells Therapy - Company Collaborations and Deal Year, 2017
Table 3: CAR-T Cells Therapy - University Collaborations and Deal Year, 2017
Table 4: CAR-T Cells Therapy collaboration Deals and Values, 2017
Table 5: Companies CAR-T Investment for future developments, 2017
Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2017
Table 7:Companies open for licensing and collaborations, 2017
Table 8:Number of Products under Development, 2017
Table 9:Number of Products under Development by Companies, 2017
Table 10:Number of Products under Development by Indication, 2017
Table 11:Number of Products Targeting CD19 Antigen, 2017
Table 12:Number of Products Targeting Other Antigens, 2017
Table 13: Number of CAR-T Ongoing Clinical Trials & Completion Year, 2017
Table 14:CAR T-cell Companies and Technologies, 2017

Figure 1: Companies Collaborations vs. Financial year, 2017
Figure 2: Number of Companies Collaborations, 2017
Figure 3: Collaborations and Upfront Deal Values (In million, $), 2017
Figure 4: Number of Products under Development, 2017
Figure 5: Number of Products under Development by Companies, 2017
Figure 6: Number of Products under Development by Indication, 2017
Figure 7: CAR-T cell Targeted Antigens (%), 2017
Figure 8: Number of Products Targeting CD19 antigen by Phase, 2017
Figure 9: Number of CAR-T Clinical Trials & Completion Year, 2017
Figure 10:CAR T-cell Companies and Technologies, 2017

Table 1: CARs Generations-Associated Target Antigens and Indications
Table 2: CAR-T Cells Therapy - Company Collaborations and Deal Year, 2017
Table 3: CAR-T Cells Therapy - University Collaborations and Deal Year, 2017
Table 4: CAR-T Cells Therapy collaboration Deals and Values, 2017
Table 5: Companies CAR-T Investment for future developments, 2017
Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2017
Table 7:Companies open for licensing and collaborations, 2017
Table 8:Number of Products under Development, 2017
Table 9:Number of Products under Development by Companies, 2017
Table 10:Number of Products under Development by Indication, 2017
Table 11:Number of Products Targeting CD19 Antigen, 2017
Table 12:Number of Products Targeting Other Antigens, 2017
Table 13: Number of CAR-T Ongoing Clinical Trials & Completion Year, 2017
Table 14:CAR T-cell Companies and Technologies, 2017

Figure 1: Companies Collaborations vs. Financial year, 2017
Figure 2: Number of Companies Collaborations, 2017
Figure 3: Collaborations and Upfront Deal Values (In million, $), 2017
Figure 4: Number of Products under Development, 2017
Figure 5: Number of Products under Development by Companies, 2017
Figure 6: Number of Products under Development by Indication, 2017
Figure 7: CAR-T cell Targeted Antigens (%), 2017
Figure 8: Number of Products Targeting CD19 antigen by Phase, 2017
Figure 9: Number of CAR-T Clinical Trials & Completion Year, 2017
Figure 10:CAR T-cell Companies and Technologies, 2017

Table 1: CARs Generations-Associated Target Antigens and Indications
Table 2: CAR-T Cells Therapy - Company Collaborations and Deal Year, 2017
Table 3: CAR-T Cells Therapy - University Collaborations and Deal Year, 2017
Table 4: CAR-T Cells Therapy collaboration Deals and Values, 2017
Table 5: Companies CAR-T Investment for future developments, 2017
Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2017
Table 7:Companies open for licensing and collaborations, 2017
Table 8:Number of Products under Development, 2017
Table 9:Number of Products under Development by Companies, 2017
Table 10:Number of Products under Development by Indication, 2017
Table 11:Number of Products Targeting CD19 Antigen, 2017
Table 12:Number of Products Targeting Other Antigens, 2017
Table 13: Number of CAR-T Ongoing Clinical Trials & Completion Year, 2017
Table 14:CAR T-cell Companies and Technologies, 2017

Figure 1: Companies Collaborations vs. Financial year, 2017
Figure 2: Number of Companies Collaborations, 2017
Figure 3: Collaborations and Upfront Deal Values (In million, $), 2017
Figure 4: Number of Products under Development, 2017
Figure 5: Number of Products under Development by Companies, 2017
Figure 6: Number of Products under Development by Indication, 2017
Figure 7: CAR-T cell Targeted Antigens (%), 2017
Figure 8: Number of Products Targeting CD19 antigen by Phase, 2017
Figure 9: Number of CAR-T Clinical Trials & Completion Year, 2017
Figure 10:CAR T-cell Companies and Technologies, 2017

Table 1: CARs Generations-Associated Target Antigens and Indications
Table 2: CAR-T Cells Therapy - Company Collaborations and Deal Year, 2017
Table 3: CAR-T Cells Therapy - University Collaborations and Deal Year, 2017
Table 4: CAR-T Cells Therapy collaboration Deals and Values, 2017
Table 5: Companies CAR-T Investment for future developments, 2017
Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2017
Table 7:Companies open for licensing and collaborations, 2017
Table 8:Number of Products under Development, 2017
Table 9:Number of Products under Development by Companies, 2017
Table 10:Number of Products under Development by Indication, 2017
Table 11:Number of Products Targeting CD19 Antigen, 2017
Table 12:Number of Products Targeting Other Antigens, 2017
Table 13: Number of CAR-T Ongoing Clinical Trials & Completion Year, 2017
Table 14:CAR T-cell Companies and Technologies, 2017

Figure 1: Companies Collaborations vs. Financial year, 2017
Figure 2: Number of Companies Collaborations, 2017
Figure 3: Collaborations and Upfront Deal Values (In million, $), 2017
Figure 4: Number of Products under Development, 2017
Figure 5: Number of Products under Development by Companies, 2017
Figure 6: Number of Products under Development by Indication, 2017
Figure 7: CAR-T cell Targeted Antigens (%), 2017
Figure 8: Number of Products Targeting CD19 antigen by Phase, 2017
Figure 9: Number of CAR-T Clinical Trials & Completion Year, 2017
Figure 10:CAR T-cell Companies and Technologies, 2017

Table 1: CARs Generations-Associated Target Antigens and Indications
Table 2: CAR-T Cells Therapy - Company Collaborations and Deal Year, 2017
Table 3: CAR-T Cells Therapy - University Collaborations and Deal Year, 2017
Table 4: CAR-T Cells Therapy collaboration Deals and Values, 2017
Table 5: Companies CAR-T Investment for future developments, 2017
Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2017
Table 7:Companies open for licensing and collaborations, 2017
Table 8:Number of Products under Development, 2017
Table 9:Number of Products under Development by Companies, 2017
Table 10:Number of Products under Development by Indication, 2017
Table 11:Number of Products Targeting CD19 Antigen, 2017
Table 12:Number of Products Targeting Other Antigens, 2017
Table 13: Number of CAR-T Ongoing Clinical Trials & Completion Year, 2017
Table 14:CAR T-cell Companies and Technologies, 2017

Figure 1: Companies Collaborations vs. Financial year, 2017
Figure 2: Number of Companies Collaborations, 2017
Figure 3: Collaborations and Upfront Deal Values (In million, $), 2017
Figure 4: Number of Products under Development, 2017
Figure 5: Number of Products under Development by Companies, 2017
Figure 6: Number of Products under Development by Indication, 2017
Figure 7: CAR-T cell Targeted Antigens (%), 2017
Figure 8: Number of Products Targeting CD19 antigen by Phase, 2017
Figure 9: Number of CAR-T Clinical Trials & Completion Year, 2017
Figure 10:CAR T-cell Companies and Technologies, 2017

Table 1: CARs Generations-Associated Target Antigens and Indications
Table 2: CAR-T Cells Therapy - Company Collaborations and Deal Year, 2017
Table 3: CAR-T Cells Therapy - University Collaborations and Deal Year, 2017
Table 4: CAR-T Cells Therapy collaboration Deals and Values, 2017
Table 5: Companies CAR-T Investment for future developments, 2017
Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2017
Table 7:Companies open for licensing and collaborations, 2017
Table 8:Number of Products under Development, 2017
Table 9:Number of Products under Development by Companies, 2017
Table 10:Number of Products under Development by Indication, 2017
Table 11:Number of Products Targeting CD19 Antigen, 2017
Table 12:Number of Products Targeting Other Antigens, 2017
Table 13: Number of CAR-T Ongoing Clinical Trials & Completion Year, 2017
Table 14:CAR T-cell Companies and Technologies, 2017

Figure 1: Companies Collaborations vs. Financial year, 2017
Figure 2: Number of Companies Collaborations, 2017
Figure 3: Collaborations and Upfront Deal Values (In million, $), 2017
Figure 4: Number of Products under Development, 2017
Figure 5: Number of Products under Development by Companies, 2017
Figure 6: Number of Products under Development by Indication, 2017
Figure 7: CAR-T cell Targeted Antigens (%), 2017
Figure 8: Number of Products Targeting CD19 antigen by Phase, 2017
Figure 9: Number of CAR-T Clinical Trials & Completion Year, 2017
Figure 10:CAR T-cell Companies and Technologies, 2017

Table 1: CARs Generations-Associated Target Antigens and Indications
Table 2: CAR-T Cells Therapy - Company Collaborations and Deal Year, 2017
Table 3: CAR-T Cells Therapy - University Collaborations and Deal Year, 2017
Table 4: CAR-T Cells Therapy collaboration Deals and Values, 2017
Table 5: Companies CAR-T Investment for future developments, 2017
Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2017
Table 7:Companies open for licensing and collaborations, 2017
Table 8:Number of Products under Development, 2017
Table 9:Number of Products under Development by Companies, 2017
Table 10:Number of Products under Development by Indication, 2017
Table 11:Number of Products Targeting CD19 Antigen, 2017
Table 12:Number of Products Targeting Other Antigens, 2017
Table 13: Number of CAR-T Ongoing Clinical Trials & Completion Year, 2017
Table 14:CAR T-cell Companies and Technologies, 2017

Figure 1: Companies Collaborations vs. Financial year, 2017
Figure 2: Number of Companies Collaborations, 2017
Figure 3: Collaborations and Upfront Deal Values (In million, $), 2017
Figure 4: Number of Products under Development, 2017
Figure 5: Number of Products under Development by Companies, 2017
Figure 6: Number of Products under Development by Indication, 2017
Figure 7: CAR-T cell Targeted Antigens (%), 2017
Figure 8: Number of Products Targeting CD19 antigen by Phase, 2017
Figure 9: Number of CAR-T Clinical Trials & Completion Year, 2017
Figure 10:CAR T-cell Companies and Technologies, 2017

Table 1: CARs Generations-Associated Target Antigens and Indications
Table 2: CAR-T Cells Therapy - Company Collaborations and Deal Year, 2017
Table 3: CAR-T Cells Therapy - University Collaborations and Deal Year, 2017
Table 4: CAR-T Cells Therapy collaboration Deals and Values, 2017
Table 5: Companies CAR-T Investment for future developments, 2017
Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2017
Table 7:Companies open for licensing and collaborations, 2017
Table 8:Number of Products under Development, 2017
Table 9:Number of Products under Development by Companies, 2017
Table 10:Number of Products under Development by Indication, 2017
Table 11:Number of Products Targeting CD19 Antigen, 2017
Table 12:Number of Products Targeting Other Antigens, 2017
Table 13: Number of CAR-T Ongoing Clinical Trials & Completion Year, 2017
Table 14:CAR T-cell Companies and Technologies, 2017

Figure 1: Companies Collaborations vs. Financial year, 2017
Figure 2: Number of Companies Collaborations, 2017
Figure 3: Collaborations and Upfront Deal Values (In million, $), 2017
Figure 4: Number of Products under Development, 2017
Figure 5: Number of Products under Development by Companies, 2017
Figure 6: Number of Products under Development by Indication, 2017
Figure 7: CAR-T cell Targeted Antigens (%), 2017
Figure 8: Number of Products Targeting CD19 antigen by Phase, 2017
Figure 9: Number of CAR-T Clinical Trials & Completion Year, 2017
Figure 10:CAR T-cell Companies and Technologies, 2017

Table 1: CARs Generations-Associated Target Antigens and Indications
Table 2: CAR-T Cells Therapy - Company Collaborations and Deal Year, 2017
Table 3: CAR-T Cells Therapy - University Collaborations and Deal Year, 2017
Table 4: CAR-T Cells Therapy collaboration Deals and Values, 2017
Table 5: Companies CAR-T Investment for future developments, 2017
Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2017
Table 7:Companies open for licensing and collaborations, 2017
Table 8:Number of Products under Development, 2017
Table 9:Number of Products under Development by Companies, 2017
Table 10:Number of Products under Development by Indication, 2017
Table 11:Number of Products Targeting CD19 Antigen, 2017
Table 12:Number of Products Targeting Other Antigens, 2017
Table 13: Number of CAR-T Ongoing Clinical Trials & Completion Year, 2017
Table 14:CAR T-cell Companies and Technologies, 2017

Figure 1: Companies Collaborations vs. Financial year, 2017
Figure 2: Number of Companies Collaborations, 2017
Figure 3: Collaborations and Upfront Deal Values (In million, $), 2017
Figure 4: Number of Products under Development, 2017
Figure 5: Number of Products under Development by Companies, 2017
Figure 6: Number of Products under Development by Indication, 2017
Figure 7: CAR-T cell Targeted Antigens (%), 2017
Figure 8: Number of Products Targeting CD19 antigen by Phase, 2017
Figure 9: Number of CAR-T Clinical Trials & Completion Year, 2017
Figure 10:CAR T-cell Companies and Technologies, 2017

Table 1: CARs Generations-Associated Target Antigens and Indications
Table 2: CAR-T Cells Therapy - Company Collaborations and Deal Year, 2017
Table 3: CAR-T Cells Therapy - University Collaborations and Deal Year, 2017
Table 4: CAR-T Cells Therapy collaboration Deals and Values, 2017
Table 5: Companies CAR-T Investment for future developments, 2017
Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2017
Table 7:Companies open for licensing and collaborations, 2017
Table 8:Number of Products under Development, 2017
Table 9:Number of Products under Development by Companies, 2017
Table 10:Number of Products under Development by Indication, 2017
Table 11:Number of Products Targeting CD19 Antigen, 2017
Table 12:Number of Products Targeting Other Antigens, 2017
Table 13: Number of CAR-T Ongoing Clinical Trials & Completion Year, 2017
Table 14:CAR T-cell Companies and Technologies, 2017

Figure 1: Companies Collaborations vs. Financial year, 2017
Figure 2: Number of Companies Collaborations, 2017
Figure 3: Collaborations and Upfront Deal Values (In million, $), 2017
Figure 4: Number of Products under Development, 2017
Figure 5: Number of Products under Development by Companies, 2017
Figure 6: Number of Products under Development by Indication, 2017
Figure 7: CAR-T cell Targeted Antigens (%), 2017
Figure 8: Number of Products Targeting CD19 antigen by Phase, 2017
Figure 9: Number of CAR-T Clinical Trials & Completion Year, 2017
Figure 10:CAR T-cell Companies and Technologies, 2017

Table 1: CARs Generations-Associated Target Antigens and Indications
Table 2: CAR-T Cells Therapy - Company Collaborations and Deal Year, 2017
Table 3: CAR-T Cells Therapy - University Collaborations and Deal Year, 2017
Table 4: CAR-T Cells Therapy collaboration Deals and Values, 2017
Table 5: Companies CAR-T Investment for future developments, 2017
Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2017
Table 7:Companies open for licensing and collaborations, 2017
Table 8:Number of Products under Development, 2017
Table 9:Number of Products under Development by Companies, 2017
Table 10:Number of Products under Development by Indication, 2017
Table 11:Number of Products Targeting CD19 Antigen, 2017
Table 12:Number of Products Targeting Other Antigens, 2017
Table 13: Number of CAR-T Ongoing Clinical Trials & Completion Year, 2017
Table 14:CAR T-cell Companies and Technologies, 2017

Figure 1: Companies Collaborations vs. Financial year, 2017
Figure 2: Number of Companies Collaborations, 2017
Figure 3: Collaborations and Upfront Deal Values (In million, $), 2017
Figure 4: Number of Products under Development, 2017
Figure 5: Number of Products under Development by Companies, 2017
Figure 6: Number of Products under Development by Indication, 2017
Figure 7: CAR-T cell Targeted Antigens (%), 2017
Figure 8: Number of Products Targeting CD19 antigen by Phase, 2017
Figure 9: Number of CAR-T Clinical Trials & Completion Year, 2017
Figure 10:CAR T-cell Companies and Technologies, 2017

Table 1: CARs Generations-Associated Target Antigens and Indications
Table 2: CAR-T Cells Therapy - Company Collaborations and Deal Year, 2017
Table 3: CAR-T Cells Therapy - University Collaborations and Deal Year, 2017
Table 4: CAR-T Cells Therapy collaboration Deals and Values, 2017
Table 5: Companies CAR-T Investment for future developments, 2017
Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2017
Table 7:Companies open for licensing and collaborations, 2017
Table 8:Number of Products under Development, 2017
Table 9:Number of Products under Development by Companies, 2017
Table 10:Number of Products under Development by Indication, 2017
Table 11:Number of Products Targeting CD19 Antigen, 2017
Table 12:Number of Products Targeting Other Antigens, 2017
Table 13: Number of CAR-T Ongoing Clinical Trials & Completion Year, 2017
Table 14:CAR T-cell Companies and Technologies, 2017

Figure 1: Companies Collaborations vs. Financial year, 2017
Figure 2: Number of Companies Collaborations, 2017
Figure 3: Collaborations and Upfront Deal Values (In million, $), 2017
Figure 4: Number of Products under Development, 2017
Figure 5: Number of Products under Development by Companies, 2017
Figure 6: Number of Products under Development by Indication, 2017
Figure 7: CAR-T cell Targeted Antigens (%), 2017
Figure 8: Number of Products Targeting CD19 antigen by Phase, 2017
Figure 9: Number of CAR-T Clinical Trials & Completion Year, 2017
Figure 10:CAR T-cell Companies and Technologies, 2017

Table 1: CARs Generations-Associated Target Antigens and Indications
Table 2: CAR-T Cells Therapy - Company Collaborations and Deal Year, 2017
Table 3: CAR-T Cells Therapy - University Collaborations and Deal Year, 2017
Table 4: CAR-T Cells Therapy collaboration Deals and Values, 2017
Table 5: Companies CAR-T Investment for future developments, 2017
Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2017
Table 7:Companies open for licensing and collaborations, 2017
Table 8:Number of Products under Development, 2017
Table 9:Number of Products under Development by Companies, 2017
Table 10:Number of Products under Development by Indication, 2017
Table 11:Number of Products Targeting CD19 Antigen, 2017
Table 12:Number of Products Targeting Other Antigens, 2017
Table 13: Number of CAR-T Ongoing Clinical Trials & Completion Year, 2017
Table 14:CAR T-cell Companies and Technologies, 2017

Figure 1: Companies Collaborations vs. Financial year, 2017
Figure 2: Number of Companies Collaborations, 2017
Figure 3: Collaborations and Upfront Deal Values (In million, $), 2017
Figure 4: Number of Products under Development, 2017
Figure 5: Number of Products under Development by Companies, 2017
Figure 6: Number of Products under Development by Indication, 2017
Figure 7: CAR-T cell Targeted Antigens (%), 2017
Figure 8: Number of Products Targeting CD19 antigen by Phase, 2017
Figure 9: Number of CAR-T Clinical Trials & Completion Year, 2017
Figure 10:CAR T-cell Companies and Technologies, 2017

Table 1: CARs Generations-Associated Target Antigens and Indications
Table 2: CAR-T Cells Therapy - Company Collaborations and Deal Year, 2017
Table 3: CAR-T Cells Therapy - University Collaborations and Deal Year, 2017
Table 4: CAR-T Cells Therapy collaboration Deals and Values, 2017
Table 5: Companies CAR-T Investment for future developments, 2017
Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2017
Table 7:Companies open for licensing and collaborations, 2017
Table 8:Number of Products under Development, 2017
Table 9:Number of Products under Development by Companies, 2017
Table 10:Number of Products under Development by Indication, 2017
Table 11:Number of Products Targeting CD19 Antigen, 2017
Table 12:Number of Products Targeting Other Antigens, 2017
Table 13: Number of CAR-T Ongoing Clinical Trials & Completion Year, 2017
Table 14:CAR T-cell Companies and Technologies, 2017

Figure 1: Companies Collaborations vs. Financial year, 2017
Figure 2: Number of Companies Collaborations, 2017
Figure 3: Collaborations and Upfront Deal Values (In million, $), 2017
Figure 4: Number of Products under Development, 2017
Figure 5: Number of Products under Development by Companies, 2017
Figure 6: Number of Products under Development by Indication, 2017
Figure 7: CAR-T cell Targeted Antigens (%), 2017
Figure 8: Number of Products Targeting CD19 antigen by Phase, 2017
Figure 9: Number of CAR-T Clinical Trials & Completion Year, 2017
Figure 10:CAR T-cell Companies and Technologies, 2017

Table 1: CARs Generations-Associated Target Antigens and Indications
Table 2: CAR-T Cells Therapy - Company Collaborations and Deal Year, 2017
Table 3: CAR-T Cells Therapy - University Collaborations and Deal Year, 2017
Table 4: CAR-T Cells Therapy collaboration Deals and Values, 2017
Table 5: Companies CAR-T Investment for future developments, 2017
Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2017
Table 7:Companies open for licensing and collaborations, 2017
Table 8:Number of Products under Development, 2017
Table 9:Number of Products under Development by Companies, 2017
Table 10:Number of Products under Development by Indication, 2017
Table 11:Number of Products Targeting CD19 Antigen, 2017
Table 12:Number of Products Targeting Other Antigens, 2017
Table 13: Number of CAR-T Ongoing Clinical Trials & Completion Year, 2017
Table 14:CAR T-cell Companies and Technologies, 2017

Figure 1: Companies Collaborations vs. Financial year, 2017
Figure 2: Number of Companies Collaborations, 2017
Figure 3: Collaborations and Upfront Deal Values (In million, $), 2017
Figure 4: Number of Products under Development, 2017
Figure 5: Number of Products under Development by Companies, 2017
Figure 6: Number of Products under Development by Indication, 2017
Figure 7: CAR-T cell Targeted Antigens (%), 2017
Figure 8: Number of Products Targeting CD19 antigen by Phase, 2017
Figure 9: Number of CAR-T Clinical Trials & Completion Year, 2017
Figure 10:CAR T-cell Companies and Technologies, 2017

Table 1: CARs Generations-Associated Target Antigens and Indications
Table 2: CAR-T Cells Therapy - Company Collaborations and Deal Year, 2017
Table 3: CAR-T Cells Therapy - University Collaborations and Deal Year, 2017
Table 4: CAR-T Cells Therapy collaboration Deals and Values, 2017
Table 5: Companies CAR-T Investment for future developments, 2017
Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2017
Table 7:Companies open for licensing and collaborations, 2017
Table 8:Number of Products under Development, 2017
Table 9:Number of Products under Development by Companies, 2017
Table 10:Number of Products under Development by Indication, 2017
Table 11:Number of Products Targeting CD19 Antigen, 2017
Table 12:Number of Products Targeting Other Antigens, 2017
Table 13: Number of CAR-T Ongoing Clinical Trials & Completion Year, 2017
Table 14:CAR T-cell Companies and Technologies, 2017

Figure 1: Companies Collaborations vs. Financial year, 2017
Figure 2: Number of Companies Collaborations, 2017
Figure 3: Collaborations and Upfront Deal Values (In million, $), 2017
Figure 4: Number of Products under Development, 2017
Figure 5: Number of Products under Development by Companies, 2017
Figure 6: Number of Products under Development by Indication, 2017
Figure 7: CAR-T cell Targeted Antigens (%), 2017
Figure 8: Number of Products Targeting CD19 antigen by Phase, 2017
Figure 9: Number of CAR-T Clinical Trials & Completion Year, 2017
Figure 10:CAR T-cell Companies and Technologies, 2017

Table 1: CARs Generations-Associated Target Antigens and Indications
Table 2: CAR-T Cells Therapy - Company Collaborations and Deal Year, 2017
Table 3: CAR-T Cells Therapy - University Collaborations and Deal Year, 2017
Table 4: CAR-T Cells Therapy collaboration Deals and Values, 2017
Table 5: Companies CAR-T Investment for future developments, 2017
Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2017
Table 7:Companies open for licensing and collaborations, 2017
Table 8:Number of Products under Development, 2017
Table 9:Number of Products under Development by Companies, 2017
Table 10:Number of Products under Development by Indication, 2017
Table 11:Number of Products Targeting CD19 Antigen, 2017
Table 12:Number of Products Targeting Other Antigens, 2017
Table 13: Number of CAR-T Ongoing Clinical Trials & Completion Year, 2017
Table 14:CAR T-cell Companies and Technologies, 2017

Figure 1: Companies Collaborations vs. Financial year, 2017
Figure 2: Number of Companies Collaborations, 2017
Figure 3: Collaborations and Upfront Deal Values (In million, $), 2017
Figure 4: Number of Products under Development, 2017
Figure 5: Number of Products under Development by Companies, 2017
Figure 6: Number of Products under Development by Indication, 2017
Figure 7: CAR-T cell Targeted Antigens (%), 2017
Figure 8: Number of Products Targeting CD19 antigen by Phase, 2017
Figure 9: Number of CAR-T Clinical Trials & Completion Year, 2017
Figure 10:CAR T-cell Companies and Technologies, 2017

Table 1: CARs Generations-Associated Target Antigens and Indications
Table 2: CAR-T Cells Therapy - Company Collaborations and Deal Year, 2017
Table 3: CAR-T Cells Therapy - University Collaborations and Deal Year, 2017
Table 4: CAR-T Cells Therapy collaboration Deals and Values, 2017
Table 5: Companies CAR-T Investment for future developments, 2017
Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2017
Table 7:Companies open for licensing and collaborations, 2017
Table 8:Number of Products under Development, 2017
Table 9:Number of Products under Development by Companies, 2017
Table 10:Number of Products under Development by Indication, 2017
Table 11:Number of Products Targeting CD19 Antigen, 2017
Table 12:Number of Products Targeting Other Antigens, 2017
Table 13: Number of CAR-T Ongoing Clinical Trials & Completion Year, 2017
Table 14:CAR T-cell Companies and Technologies, 2017

Figure 1: Companies Collaborations vs. Financial year, 2017
Figure 2: Number of Companies Collaborations, 2017
Figure 3: Collaborations and Upfront Deal Values (In million, $), 2017
Figure 4: Number of Products under Development, 2017
Figure 5: Number of Products under Development by Companies, 2017
Figure 6: Number of Products under Development by Indication, 2017
Figure 7: CAR-T cell Targeted Antigens (%), 2017
Figure 8: Number of Products Targeting CD19 antigen by Phase, 2017
Figure 9: Number of CAR-T Clinical Trials & Completion Year, 2017
Figure 10:CAR T-cell Companies and Technologies, 2017

Table 1: CARs Generations-Associated Target Antigens and Indications
Table 2: CAR-T Cells Therapy - Company Collaborations and Deal Year, 2017
Table 3: CAR-T Cells Therapy - University Collaborations and Deal Year, 2017
Table 4: CAR-T Cells Therapy collaboration Deals and Values, 2017
Table 5: Companies CAR-T Investment for future developments, 2017
Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2017
Table 7:Companies open for licensing and collaborations, 2017
Table 8:Number of Products under Development, 2017
Table 9:Number of Products under Development by Companies, 2017
Table 10:Number of Products under Development by Indication, 2017
Table 11:Number of Products Targeting CD19 Antigen, 2017
Table 12:Number of Products Targeting Other Antigens, 2017
Table 13: Number of CAR-T Ongoing Clinical Trials & Completion Year, 2017
Table 14:CAR T-cell Companies and Technologies, 2017

Figure 1: Companies Collaborations vs. Financial year, 2017
Figure 2: Number of Companies Collaborations, 2017
Figure 3: Collaborations and Upfront Deal Values (In million, $), 2017
Figure 4: Number of Products under Development, 2017
Figure 5: Number of Products under Development by Companies, 2017
Figure 6: Number of Products under Development by Indication, 2017
Figure 7: CAR-T cell Targeted Antigens (%), 2017
Figure 8: Number of Products Targeting CD19 antigen by Phase, 2017
Figure 9: Number of CAR-T Clinical Trials & Completion Year, 2017
Figure 10:CAR T-cell Companies and Technologies, 2017

Table 1: CARs Generations-Associated Target Antigens and Indications
Table 2: CAR-T Cells Therapy - Company Collaborations and Deal Year, 2017
Table 3: CAR-T Cells Therapy - University Collaborations and Deal Year, 2017
Table 4: CAR-T Cells Therapy collaboration Deals and Values, 2017
Table 5: Companies CAR-T Investment for future developments, 2017
Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2017
Table 7:Companies open for licensing and collaborations, 2017
Table 8:Number of Products under Development, 2017
Table 9:Number of Products under Development by Companies, 2017
Table 10:Number of Products under Development by Indication, 2017
Table 11:Number of Products Targeting CD19 Antigen, 2017
Table 12:Number of Products Targeting Other Antigens, 2017
Table 13: Number of CAR-T Ongoing Clinical Trials & Completion Year, 2017
Table 14:CAR T-cell Companies and Technologies, 2017

Figure 1: Companies Collaborations vs. Financial year, 2017
Figure 2: Number of Companies Collaborations, 2017
Figure 3: Collaborations and Upfront Deal Values (In million, $), 2017
Figure 4: Number of Products under Development, 2017
Figure 5: Number of Products under Development by Companies, 2017
Figure 6: Number of Products under Development by Indication, 2017
Figure 7: CAR-T cell Targeted Antigens (%), 2017
Figure 8: Number of Products Targeting CD19 antigen by Phase, 2017
Figure 9: Number of CAR-T Clinical Trials & Completion Year, 2017
Figure 10:CAR T-cell Companies and Technologies, 2017

Table 1: CARs Generations-Associated Target Antigens and Indications
Table 2: CAR-T Cells Therapy - Company Collaborations and Deal Year, 2017
Table 3: CAR-T Cells Therapy - University Collaborations and Deal Year, 2017
Table 4: CAR-T Cells Therapy collaboration Deals and Values, 2017
Table 5: Companies CAR-T Investment for future developments, 2017
Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2017
Table 7:Companies open for licensing and collaborations, 2017
Table 8:Number of Products under Development, 2017
Table 9:Number of Products under Development by Companies, 2017
Table 10:Number of Products under Development by Indication, 2017
Table 11:Number of Products Targeting CD19 Antigen, 2017
Table 12:Number of Products Targeting Other Antigens, 2017
Table 13: Number of CAR-T Ongoing Clinical Trials & Completion Year, 2017
Table 14:CAR T-cell Companies and Technologies, 2017

Figure 1: Companies Collaborations vs. Financial year, 2017
Figure 2: Number of Companies Collaborations, 2017
Figure 3: Collaborations and Upfront Deal Values (In million, $), 2017
Figure 4: Number of Products under Development, 2017
Figure 5: Number of Products under Development by Companies, 2017
Figure 6: Number of Products under Development by Indication, 2017
Figure 7: CAR-T cell Targeted Antigens (%), 2017
Figure 8: Number of Products Targeting CD19 antigen by Phase, 2017
Figure 9: Number of CAR-T Clinical Trials & Completion Year, 2017
Figure 10:CAR T-cell Companies and Technologies, 2017

Table 1: CARs Generations-Associated Target Antigens and Indications
Table 2: CAR-T Cells Therapy - Company Collaborations and Deal Year, 2017
Table 3: CAR-T Cells Therapy - University Collaborations and Deal Year, 2017
Table 4: CAR-T Cells Therapy collaboration Deals and Values, 2017
Table 5: Companies CAR-T Investment for future developments, 2017
Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2017
Table 7:Companies open for licensing and collaborations, 2017
Table 8:Number of Products under Development, 2017
Table 9:Number of Products under Development by Companies, 2017
Table 10:Number of Products under Development by Indication, 2017
Table 11:Number of Products Targeting CD19 Antigen, 2017
Table 12:Number of Products Targeting Other Antigens, 2017
Table 13: Number of CAR-T Ongoing Clinical Trials & Completion Year, 2017
Table 14:CAR T-cell Companies and Technologies, 2017

Figure 1: Companies Collaborations vs. Financial year, 2017
Figure 2: Number of Companies Collaborations, 2017
Figure 3: Collaborations and Upfront Deal Values (In million, $), 2017
Figure 4: Number of Products under Development, 2017
Figure 5: Number of Products under Development by Companies, 2017
Figure 6: Number of Products under Development by Indication, 2017
Figure 7: CAR-T cell Targeted Antigens (%), 2017
Figure 8: Number of Products Targeting CD19 antigen by Phase, 2017
Figure 9: Number of CAR-T Clinical Trials & Completion Year, 2017
Figure 10:CAR T-cell Companies and Technologies, 2017

Table 1: CARs Generations-Associated Target Antigens and Indications
Table 2: CAR-T Cells Therapy - Company Collaborations and Deal Year, 2017
Table 3: CAR-T Cells Therapy - University Collaborations and Deal Year, 2017
Table 4: CAR-T Cells Therapy collaboration Deals and Values, 2017
Table 5: Companies CAR-T Investment for future developments, 2017
Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2017
Table 7:Companies open for licensing and collaborations, 2017
Table 8:Number of Products under Development, 2017
Table 9:Number of Products under Development by Companies, 2017
Table 10:Number of Products under Development by Indication, 2017
Table 11:Number of Products Targeting CD19 Antigen, 2017
Table 12:Number of Products Targeting Other Antigens, 2017
Table 13: Number of CAR-T Ongoing Clinical Trials & Completion Year, 2017
Table 14:CAR T-cell Companies and Technologies, 2017

Figure 1: Companies Collaborations vs. Financial year, 2017
Figure 2: Number of Companies Collaborations, 2017
Figure 3: Collaborations and Upfront Deal Values (In million, $), 2017
Figure 4: Number of Products under Development, 2017
Figure 5: Number of Products under Development by Companies, 2017
Figure 6: Number of Products under Development by Indication, 2017
Figure 7: CAR-T cell Targeted Antigens (%), 2017
Figure 8: Number of Products Targeting CD19 antigen by Phase, 2017
Figure 9: Number of CAR-T Clinical Trials & Completion Year, 2017
Figure 10:CAR T-cell Companies and Technologies, 2017

Table 1: CARs Generations-Associated Target Antigens and Indications
Table 2: CAR-T Cells Therapy - Company Collaborations and Deal Year, 2017
Table 3: CAR-T Cells Therapy - University Collaborations and Deal Year, 2017
Table 4: CAR-T Cells Therapy collaboration Deals and Values, 2017
Table 5: Companies CAR-T Investment for future developments, 2017
Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2017
Table 7:Companies open for licensing and collaborations, 2017
Table 8:Number of Products under Development, 2017
Table 9:Number of Products under Development by Companies, 2017
Table 10:Number of Products under Development by Indication, 2017
Table 11:Number of Products Targeting CD19 Antigen, 2017
Table 12:Number of Products Targeting Other Antigens, 2017
Table 13: Number of CAR-T Ongoing Clinical Trials & Completion Year, 2017
Table 14:CAR T-cell Companies and Technologies, 2017

Figure 1: Companies Collaborations vs. Financial year, 2017
Figure 2: Number of Companies Collaborations, 2017
Figure 3: Collaborations and Upfront Deal Values (In million, $), 2017
Figure 4: Number of Products under Development, 2017
Figure 5: Number of Products under Development by Companies, 2017
Figure 6: Number of Products under Development by Indication, 2017
Figure 7: CAR-T cell Targeted Antigens (%), 2017
Figure 8: Number of Products Targeting CD19 antigen by Phase, 2017
Figure 9: Number of CAR-T Clinical Trials & Completion Year, 2017
Figure 10:CAR T-cell Companies and Technologies, 2017

Table 1: CARs Generations-Associated Target Antigens and Indications
Table 2: CAR-T Cells Therapy - Company Collaborations and Deal Year, 2017
Table 3: CAR-T Cells Therapy - University Collaborations and Deal Year, 2017
Table 4: CAR-T Cells Therapy collaboration Deals and Values, 2017
Table 5: Companies CAR-T Investment for future developments, 2017
Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2017
Table 7:Companies open for licensing and collaborations, 2017
Table 8:Number of Products under Development, 2017
Table 9:Number of Products under Development by Companies, 2017
Table 10:Number of Products under Development by Indication, 2017
Table 11:Number of Products Targeting CD19 Antigen, 2017
Table 12:Number of Products Targeting Other Antigens, 2017
Table 13: Number of CAR-T Ongoing Clinical Trials & Completion Year, 2017
Table 14:CAR T-cell Companies and Technologies, 2017

Figure 1: Companies Collaborations vs. Financial year, 2017
Figure 2: Number of Companies Collaborations, 2017
Figure 3: Collaborations and Upfront Deal Values (In million, $), 2017
Figure 4: Number of Products under Development, 2017
Figure 5: Number of Products under Development by Companies, 2017
Figure 6: Number of Products under Development by Indication, 2017
Figure 7: CAR-T cell Targeted Antigens (%), 2017
Figure 8: Number of Products Targeting CD19 antigen by Phase, 2017
Figure 9: Number of CAR-T Clinical Trials & Completion Year, 2017
Figure 10:CAR T-cell Companies and Technologies, 2017

Table 1: CARs Generations-Associated Target Antigens and Indications
Table 2: CAR-T Cells Therapy - Company Collaborations and Deal Year, 2017
Table 3: CAR-T Cells Therapy - University Collaborations and Deal Year, 2017
Table 4: CAR-T Cells Therapy collaboration Deals and Values, 2017
Table 5: Companies CAR-T Investment for future developments, 2017
Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2017
Table 7:Companies open for licensing and collaborations, 2017
Table 8:Number of Products under Development, 2017
Table 9:Number of Products under Development by Companies, 2017
Table 10:Number of Products under Development by Indication, 2017
Table 11:Number of Products Targeting CD19 Antigen, 2017
Table 12:Number of Products Targeting Other Antigens, 2017
Table 13: Number of CAR-T Ongoing Clinical Trials & Completion Year, 2017
Table 14:CAR T-cell Companies and Technologies, 2017

Figure 1: Companies Collaborations vs. Financial year, 2017
Figure 2: Number of Companies Collaborations, 2017
Figure 3: Collaborations and Upfront Deal Values (In million, $), 2017
Figure 4: Number of Products under Development, 2017
Figure 5: Number of Products under Development by Companies, 2017
Figure 6: Number of Products under Development by Indication, 2017
Figure 7: CAR-T cell Targeted Antigens (%), 2017
Figure 8: Number of Products Targeting CD19 antigen by Phase, 2017
Figure 9: Number of CAR-T Clinical Trials & Completion Year, 2017
Figure 10:CAR T-cell Companies and Technologies, 2017

Table 1: CARs Generations-Associated Target Antigens and Indications
Table 2: CAR-T Cells Therapy - Company Collaborations and Deal Year, 2017
Table 3: CAR-T Cells Therapy - University Collaborations and Deal Year, 2017
Table 4: CAR-T Cells Therapy collaboration Deals and Values, 2017
Table 5: Companies CAR-T Investment for future developments, 2017
Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2017
Table 7:Companies open for licensing and collaborations, 2017
Table 8:Number of Products under Development, 2017
Table 9:Number of Products under Development by Companies, 2017
Table 10:Number of Products under Development by Indication, 2017
Table 11:Number of Products Targeting CD19 Antigen, 2017
Table 12:Number of Products Targeting Other Antigens, 2017
Table 13: Number of CAR-T Ongoing Clinical Trials & Completion Year, 2017
Table 14:CAR T-cell Companies and Technologies, 2017

Figure 1: Companies Collaborations vs. Financial year, 2017
Figure 2: Number of Companies Collaborations, 2017
Figure 3: Collaborations and Upfront Deal Values (In million, $), 2017
Figure 4: Number of Products under Development, 2017
Figure 5: Number of Products under Development by Companies, 2017
Figure 6: Number of Products under Development by Indication, 2017
Figure 7: CAR-T cell Targeted Antigens (%), 2017
Figure 8: Number of Products Targeting CD19 antigen by Phase, 2017
Figure 9: Number of CAR-T Clinical Trials & Completion Year, 2017
Figure 10:CAR T-cell Companies and Technologies, 2017

Table 1: CARs Generations-Associated Target Antigens and Indications
Table 2: CAR-T Cells Therapy - Company Collaborations and Deal Year, 2017
Table 3: CAR-T Cells Therapy - University Collaborations and Deal Year, 2017
Table 4: CAR-T Cells Therapy collaboration Deals and Values, 2017
Table 5: Companies CAR-T Investment for future developments, 2017
Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2017
Table 7:Companies open for licensing and collaborations, 2017
Table 8:Number of Products under Development, 2017
Table 9:Number of Products under Development by Companies, 2017
Table 10:Number of Products under Development by Indication, 2017
Table 11:Number of Products Targeting CD19 Antigen, 2017
Table 12:Number of Products Targeting Other Antigens, 2017
Table 13: Number of CAR-T Ongoing Clinical Trials & Completion Year, 2017
Table 14:CAR T-cell Companies and Technologies, 2017

Figure 1: Companies Collaborations vs. Financial year, 2017
Figure 2: Number of Companies Collaborations, 2017
Figure 3: Collaborations and Upfront Deal Values (In million, $), 2017
Figure 4: Number of Products under Development, 2017
Figure 5: Number of Products under Development by Companies, 2017
Figure 6: Number of Products under Development by Indication, 2017
Figure 7: CAR-T cell Targeted Antigens (%), 2017
Figure 8: Number of Products Targeting CD19 antigen by Phase, 2017
Figure 9: Number of CAR-T Clinical Trials & Completion Year, 2017
Figure 10:CAR T-cell Companies and Technologies, 2017

Table 1: CARs Generations-Associated Target Antigens and Indications
Table 2: CAR-T Cells Therapy - Company Collaborations and Deal Year, 2017
Table 3: CAR-T Cells Therapy - University Collaborations and Deal Year, 2017
Table 4: CAR-T Cells Therapy collaboration Deals and Values, 2017
Table 5: Companies CAR-T Investment for future developments, 2017
Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2017
Table 7:Companies open for licensing and collaborations, 2017
Table 8:Number of Products under Development, 2017
Table 9:Number of Products under Development by Companies, 2017
Table 10:Number of Products under Development by Indication, 2017
Table 11:Number of Products Targeting CD19 Antigen, 2017
Table 12:Number of Products Targeting Other Antigens, 2017
Table 13: Number of CAR-T Ongoing Clinical Trials & Completion Year, 2017
Table 14:CAR T-cell Companies and Technologies, 2017

Figure 1: Companies Collaborations vs. Financial year, 2017
Figure 2: Number of Companies Collaborations, 2017
Figure 3: Collaborations and Upfront Deal Values (In million, $), 2017
Figure 4: Number of Products under Development, 2017
Figure 5: Number of Products under Development by Companies, 2017
Figure 6: Number of Products under Development by Indication, 2017
Figure 7: CAR-T cell Targeted Antigens (%), 2017
Figure 8: Number of Products Targeting CD19 antigen by Phase, 2017
Figure 9: Number of CAR-T Clinical Trials & Completion Year, 2017
Figure 10:CAR T-cell Companies and Technologies, 2017

Table 1: CARs Generations-Associated Target Antigens and Indications
Table 2: CAR-T Cells Therapy - Company Collaborations and Deal Year, 2017
Table 3: CAR-T Cells Therapy - University Collaborations and Deal Year, 2017
Table 4: CAR-T Cells Therapy collaboration Deals and Values, 2017
Table 5: Companies CAR-T Investment for future developments, 2017
Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2017
Table 7:Companies open for licensing and collaborations, 2017
Table 8:Number of Products under Development, 2017
Table 9:Number of Products under Development by Companies, 2017
Table 10:Number of Products under Development by Indication, 2017
Table 11:Number of Products Targeting CD19 Antigen, 2017
Table 12:Number of Products Targeting Other Antigens, 2017
Table 13: Number of CAR-T Ongoing Clinical Trials & Completion Year, 2017
Table 14:CAR T-cell Companies and Technologies, 2017

Figure 1: Companies Collaborations vs. Financial year, 2017
Figure 2: Number of Companies Collaborations, 2017
Figure 3: Collaborations and Upfront Deal Values (In million, $), 2017
Figure 4: Number of Products under Development, 2017
Figure 5: Number of Products under Development by Companies, 2017
Figure 6: Number of Products under Development by Indication, 2017
Figure 7: CAR-T cell Targeted Antigens (%), 2017
Figure 8: Number of Products Targeting CD19 antigen by Phase, 2017
Figure 9: Number of CAR-T Clinical Trials & Completion Year, 2017
Figure 10:CAR T-cell Companies and Technologies, 2017

Table 1: CARs Generations-Associated Target Antigens and Indications
Table 2: CAR-T Cells Therapy - Company Collaborations and Deal Year, 2017
Table 3: CAR-T Cells Therapy - University Collaborations and Deal Year, 2017
Table 4: CAR-T Cells Therapy collaboration Deals and Values, 2017
Table 5: Companies CAR-T Investment for future developments, 2017
Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2017
Table 7:Companies open for licensing and collaborations, 2017
Table 8:Number of Products under Development, 2017
Table 9:Number of Products under Development by Companies, 2017
Table 10:Number of Products under Development by Indication, 2017
Table 11:Number of Products Targeting CD19 Antigen, 2017
Table 12:Number of Products Targeting Other Antigens, 2017
Table 13: Number of CAR-T Ongoing Clinical Trials & Completion Year, 2017
Table 14:CAR T-cell Companies and Technologies, 2017

Figure 1: Companies Collaborations vs. Financial year, 2017
Figure 2: Number of Companies Collaborations, 2017
Figure 3: Collaborations and Upfront Deal Values (In million, $), 2017
Figure 4: Number of Products under Development, 2017
Figure 5: Number of Products under Development by Companies, 2017
Figure 6: Number of Products under Development by Indication, 2017
Figure 7: CAR-T cell Targeted Antigens (%), 2017
Figure 8: Number of Products Targeting CD19 antigen by Phase, 2017
Figure 9: Number of CAR-T Clinical Trials & Completion Year, 2017
Figure 10:CAR T-cell Companies and Technologies, 2017

Table 1: CARs Generations-Associated Target Antigens and Indications
Table 2: CAR-T Cells Therapy - Company Collaborations and Deal Year, 2017
Table 3: CAR-T Cells Therapy - University Collaborations and Deal Year, 2017
Table 4: CAR-T Cells Therapy collaboration Deals and Values, 2017
Table 5: Companies CAR-T Investment for future developments, 2017
Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2017
Table 7:Companies open for licensing and collaborations, 2017
Table 8:Number of Products under Development, 2017
Table 9:Number of Products under Development by Companies, 2017
Table 10:Number of Products under Development by Indication, 2017
Table 11:Number of Products Targeting CD19 Antigen, 2017
Table 12:Number of Products Targeting Other Antigens, 2017
Table 13: Number of CAR-T Ongoing Clinical Trials & Completion Year, 2017
Table 14:CAR T-cell Companies and Technologies, 2017

Figure 1: Companies Collaborations vs. Financial year, 2017
Figure 2: Number of Companies Collaborations, 2017
Figure 3: Collaborations and Upfront Deal Values (In million, $), 2017
Figure 4: Number of Products under Development, 2017
Figure 5: Number of Products under Development by Companies, 2017
Figure 6: Number of Products under Development by Indication, 2017
Figure 7: CAR-T cell Targeted Antigens (%), 2017
Figure 8: Number of Products Targeting CD19 antigen by Phase, 2017
Figure 9: Number of CAR-T Clinical Trials & Completion Year, 2017
Figure 10:CAR T-cell Companies and Technologies, 2017

Table 1: CARs Generations-Associated Target Antigens and Indications
Table 2: CAR-T Cells Therapy - Company Collaborations and Deal Year, 2017
Table 3: CAR-T Cells Therapy - University Collaborations and Deal Year, 2017
Table 4: CAR-T Cells Therapy collaboration Deals and Values, 2017
Table 5: Companies CAR-T Investment for future developments, 2017
Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2017
Table 7:Companies open for licensing and collaborations, 2017
Table 8:Number of Products under Development, 2017
Table 9:Number of Products under Development by Companies, 2017
Table 10:Number of Products under Development by Indication, 2017
Table 11:Number of Products Targeting CD19 Antigen, 2017
Table 12:Number of Products Targeting Other Antigens, 2017
Table 13: Number of CAR-T Ongoing Clinical Trials & Completion Year, 2017
Table 14:CAR T-cell Companies and Technologies, 2017

Figure 1: Companies Collaborations vs. Financial year, 2017
Figure 2: Number of Companies Collaborations, 2017
Figure 3: Collaborations and Upfront Deal Values (In million, $), 2017
Figure 4: Number of Products under Development, 2017
Figure 5: Number of Products under Development by Companies, 2017
Figure 6: Number of Products under Development by Indication, 2017
Figure 7: CAR-T cell Targeted Antigens (%), 2017
Figure 8: Number of Products Targeting CD19 antigen by Phase, 2017
Figure 9: Number of CAR-T Clinical Trials & Completion Year, 2017
Figure 10:CAR T-cell Companies and Technologies, 2017

Table 1: CARs Generations-Associated Target Antigens and Indications
Table 2: CAR-T Cells Therapy - Company Collaborations and Deal Year, 2017
Table 3: CAR-T Cells Therapy - University Collaborations and Deal Year, 2017
Table 4: CAR-T Cells Therapy collaboration Deals and Values, 2017
Table 5: Companies CAR-T Investment for future developments, 2017
Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2017
Table 7:Companies open for licensing and collaborations, 2017
Table 8:Number of Products under Development, 2017
Table 9:Number of Products under Development by Companies, 2017
Table 10:Number of Products under Development by Indication, 2017
Table 11:Number of Products Targeting CD19 Antigen, 2017
Table 12:Number of Products Targeting Other Antigens, 2017
Table 13: Number of CAR-T Ongoing Clinical Trials & Completion Year, 2017
Table 14:CAR T-cell Companies and Technologies, 2017

Figure 1: Companies Collaborations vs. Financial year, 2017
Figure 2: Number of Companies Collaborations, 2017
Figure 3: Collaborations and Upfront Deal Values (In million, $), 2017
Figure 4: Number of Products under Development, 2017
Figure 5: Number of Products under Development by Companies, 2017
Figure 6: Number of Products under Development by Indication, 2017
Figure 7: CAR-T cell Targeted Antigens (%), 2017
Figure 8: Number of Products Targeting CD19 antigen by Phase, 2017
Figure 9: Number of CAR-T Clinical Trials & Completion Year, 2017
Figure 10:CAR T-cell Companies and Technologies, 2017

Table 1: CARs Generations-Associated Target Antigens and Indications
Table 2: CAR-T Cells Therapy - Company Collaborations and Deal Year, 2017
Table 3: CAR-T Cells Therapy - University Collaborations and Deal Year, 2017
Table 4: CAR-T Cells Therapy collaboration Deals and Values, 2017
Table 5: Companies CAR-T Investment for future developments, 2017
Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2017
Table 7:Companies open for licensing and collaborations, 2017
Table 8:Number of Products under Development, 2017
Table 9:Number of Products under Development by Companies, 2017
Table 10:Number of Products under Development by Indication, 2017
Table 11:Number of Products Targeting CD19 Antigen, 2017
Table 12:Number of Products Targeting Other Antigens, 2017
Table 13: Number of CAR-T Ongoing Clinical Trials & Completion Year, 2017
Table 14:CAR T-cell Companies and Technologies, 2017

Figure 1: Companies Collaborations vs. Financial year, 2017
Figure 2: Number of Companies Collaborations, 2017
Figure 3: Collaborations and Upfront Deal Values (In million, $), 2017
Figure 4: Number of Products under Development, 2017
Figure 5: Number of Products under Development by Companies, 2017
Figure 6: Number of Products under Development by Indication, 2017
Figure 7: CAR-T cell Targeted Antigens (%), 2017
Figure 8: Number of Products Targeting CD19 antigen by Phase, 2017
Figure 9: Number of CAR-T Clinical Trials & Completion Year, 2017
Figure 10:CAR T-cell Companies and Technologies, 2017

Table 1: CARs Generations-Associated Target Antigens and Indications
Table 2: CAR-T Cells Therapy - Company Collaborations and Deal Year, 2017
Table 3: CAR-T Cells Therapy - University Collaborations and Deal Year, 2017
Table 4: CAR-T Cells Therapy collaboration Deals and Values, 2017
Table 5: Companies CAR-T Investment for future developments, 2017
Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2017
Table 7:Companies open for licensing and collaborations, 2017
Table 8:Number of Products under Development, 2017
Table 9:Number of Products under Development by Companies, 2017
Table 10:Number of Products under Development by Indication, 2017
Table 11:Number of Products Targeting CD19 Antigen, 2017
Table 12:Number of Products Targeting Other Antigens, 2017
Table 13: Number of CAR-T Ongoing Clinical Trials & Completion Year, 2017
Table 14:CAR T-cell Companies and Technologies, 2017

Figure 1: Companies Collaborations vs. Financial year, 2017
Figure 2: Number of Companies Collaborations, 2017
Figure 3: Collaborations and Upfront Deal Values (In million, $), 2017
Figure 4: Number of Products under Development, 2017
Figure 5: Number of Products under Development by Companies, 2017
Figure 6: Number of Products under Development by Indication, 2017
Figure 7: CAR-T cell Targeted Antigens (%), 2017
Figure 8: Number of Products Targeting CD19 antigen by Phase, 2017
Figure 9: Number of CAR-T Clinical Trials & Completion Year, 2017
Figure 10:CAR T-cell Companies and Technologies, 2017

Table 1: CARs Generations-Associated Target Antigens and Indications
Table 2: CAR-T Cells Therapy - Company Collaborations and Deal Year, 2017
Table 3: CAR-T Cells Therapy - University Collaborations and Deal Year, 2017
Table 4: CAR-T Cells Therapy collaboration Deals and Values, 2017
Table 5: Companies CAR-T Investment for future developments, 2017
Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2017
Table 7:Companies open for licensing and collaborations, 2017
Table 8:Number of Products under Development, 2017
Table 9:Number of Products under Development by Companies, 2017
Table 10:Number of Products under Development by Indication, 2017
Table 11:Number of Products Targeting CD19 Antigen, 2017
Table 12:Number of Products Targeting Other Antigens, 2017
Table 13: Number of CAR-T Ongoing Clinical Trials & Completion Year, 2017
Table 14:CAR T-cell Companies and Technologies, 2017

Figure 1: Companies Collaborations vs. Financial year, 2017
Figure 2: Number of Companies Collaborations, 2017
Figure 3: Collaborations and Upfront Deal Values (In million, $), 2017
Figure 4: Number of Products under Development, 2017
Figure 5: Number of Products under Development by Companies, 2017
Figure 6: Number of Products under Development by Indication, 2017
Figure 7: CAR-T cell Targeted Antigens (%), 2017
Figure 8: Number of Products Targeting CD19 antigen by Phase, 2017
Figure 9: Number of CAR-T Clinical Trials & Completion Year, 2017
Figure 10:CAR T-cell Companies and Technologies, 2017

Table 1: CARs Generations-Associated Target Antigens and Indications
Table 2: CAR-T Cells Therapy - Company Collaborations and Deal Year, 2017
Table 3: CAR-T Cells Therapy - University Collaborations and Deal Year, 2017
Table 4: CAR-T Cells Therapy collaboration Deals and Values, 2017
Table 5: Companies CAR-T Investment for future developments, 2017
Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2017
Table 7:Companies open for licensing and collaborations, 2017
Table 8:Number of Products under Development, 2017
Table 9:Number of Products under Development by Companies, 2017
Table 10:Number of Products under Development by Indication, 2017
Table 11:Number of Products Targeting CD19 Antigen, 2017
Table 12:Number of Products Targeting Other Antigens, 2017
Table 13: Number of CAR-T Ongoing Clinical Trials & Completion Year, 2017
Table 14:CAR T-cell Companies and Technologies, 2017

Figure 1: Companies Collaborations vs. Financial year, 2017
Figure 2: Number of Companies Collaborations, 2017
Figure 3: Collaborations and Upfront Deal Values (In million, $), 2017
Figure 4: Number of Products under Development, 2017
Figure 5: Number of Products under Development by Companies, 2017
Figure 6: Number of Products under Development by Indication, 2017
Figure 7: CAR-T cell Targeted Antigens (%), 2017
Figure 8: Number of Products Targeting CD19 antigen by Phase, 2017
Figure 9: Number of CAR-T Clinical Trials & Completion Year, 2017
Figure 10:CAR T-cell Companies and Technologies, 2017

Table 1: CARs Generations-Associated Target Antigens and Indications
Table 2: CAR-T Cells Therapy - Company Collaborations and Deal Year, 2017
Table 3: CAR-T Cells Therapy - University Collaborations and Deal Year, 2017
Table 4: CAR-T Cells Therapy collaboration Deals and Values, 2017
Table 5: Companies CAR-T Investment for future developments, 2017
Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2017
Table 7:Companies open for licensing and collaborations, 2017
Table 8:Number of Products under Development, 2017
Table 9:Number of Products under Development by Companies, 2017
Table 10:Number of Products under Development by Indication, 2017
Table 11:Number of Products Targeting CD19 Antigen, 2017
Table 12:Number of Products Targeting Other Antigens, 2017
Table 13: Number of CAR-T Ongoing Clinical Trials & Completion Year, 2017
Table 14:CAR T-cell Companies and Technologies, 2017

Figure 1: Companies Collaborations vs. Financial year, 2017
Figure 2: Number of Companies Collaborations, 2017
Figure 3: Collaborations and Upfront Deal Values (In million, $), 2017
Figure 4: Number of Products under Development, 2017
Figure 5: Number of Products under Development by Companies, 2017
Figure 6: Number of Products under Development by Indication, 2017
Figure 7: CAR-T cell Targeted Antigens (%), 2017
Figure 8: Number of Products Targeting CD19 antigen by Phase, 2017
Figure 9: Number of CAR-T Clinical Trials & Completion Year, 2017
Figure 10:CAR T-cell Companies and Technologies, 2017

Table 1: CARs Generations-Associated Target Antigens and Indications
Table 2: CAR-T Cells Therapy - Company Collaborations and Deal Year, 2017
Table 3: CAR-T Cells Therapy - University Collaborations and Deal Year, 2017
Table 4: CAR-T Cells Therapy collaboration Deals and Values, 2017
Table 5: Companies CAR-T Investment for future developments, 2017
Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2017
Table 7:Companies open for licensing and collaborations, 2017
Table 8:Number of Products under Development, 2017
Table 9:Number of Products under Development by Companies, 2017
Table 10:Number of Products under Development by Indication, 2017
Table 11:Number of Products Targeting CD19 Antigen, 2017
Table 12:Number of Products Targeting Other Antigens, 2017
Table 13: Number of CAR-T Ongoing Clinical Trials & Completion Year, 2017
Table 14:CAR T-cell Companies and Technologies, 2017

Figure 1: Companies Collaborations vs. Financial year, 2017
Figure 2: Number of Companies Collaborations, 2017
Figure 3: Collaborations and Upfront Deal Values (In million, $), 2017
Figure 4: Number of Products under Development, 2017
Figure 5: Number of Products under Development by Companies, 2017
Figure 6: Number of Products under Development by Indication, 2017
Figure 7: CAR-T cell Targeted Antigens (%), 2017
Figure 8: Number of Products Targeting CD19 antigen by Phase, 2017
Figure 9: Number of CAR-T Clinical Trials & Completion Year, 2017
Figure 10:CAR T-cell Companies and Technologies, 2017

Table 1: CARs Generations-Associated Target Antigens and Indications
Table 2: CAR-T Cells Therapy - Company Collaborations and Deal Year, 2017
Table 3: CAR-T Cells Therapy - University Collaborations and Deal Year, 2017
Table 4: CAR-T Cells Therapy collaboration Deals and Values, 2017
Table 5: Companies CAR-T Investment for future developments, 2017
Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2017
Table 7:Companies open for licensing and collaborations, 2017
Table 8:Number of Products under Development, 2017
Table 9:Number of Products under Development by Companies, 2017
Table 10:Number of Products under Development by Indication, 2017
Table 11:Number of Products Targeting CD19 Antigen, 2017
Table 12:Number of Products Targeting Other Antigens, 2017
Table 13: Number of CAR-T Ongoing Clinical Trials & Completion Year, 2017
Table 14:CAR T-cell Companies and Technologies, 2017

Figure 1: Companies Collaborations vs. Financial year, 2017
Figure 2: Number of Companies Collaborations, 2017
Figure 3: Collaborations and Upfront Deal Values (In million, $), 2017
Figure 4: Number of Products under Development, 2017
Figure 5: Number of Products under Development by Companies, 2017
Figure 6: Number of Products under Development by Indication, 2017
Figure 7: CAR-T cell Targeted Antigens (%), 2017
Figure 8: Number of Products Targeting CD19 antigen by Phase, 2017
Figure 9: Number of CAR-T Clinical Trials & Completion Year, 2017
Figure 10:CAR T-cell Companies and Technologies, 2017

Table 1: CARs Generations-Associated Target Antigens and Indications
Table 2: CAR-T Cells Therapy - Company Collaborations and Deal Year, 2017
Table 3: CAR-T Cells Therapy - University Collaborations and Deal Year, 2017
Table 4: CAR-T Cells Therapy collaboration Deals and Values, 2017
Table 5: Companies CAR-T Investment for future developments, 2017
Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2017
Table 7:Companies open for licensing and collaborations, 2017
Table 8:Number of Products under Development, 2017
Table 9:Number of Products under Development by Companies, 2017
Table 10:Number of Products under Development by Indication, 2017
Table 11:Number of Products Targeting CD19 Antigen, 2017
Table 12:Number of Products Targeting Other Antigens, 2017
Table 13: Number of CAR-T Ongoing Clinical Trials & Completion Year, 2017
Table 14:CAR T-cell Companies and Technologies, 2017

Figure 1: Companies Collaborations vs. Financial year, 2017
Figure 2: Number of Companies Collaborations, 2017
Figure 3: Collaborations and Upfront Deal Values (In million, $), 2017
Figure 4: Number of Products under Development, 2017
Figure 5: Number of Products under Development by Companies, 2017
Figure 6: Number of Products under Development by Indication, 2017
Figure 7: CAR-T cell Targeted Antigens (%), 2017
Figure 8: Number of Products Targeting CD19 antigen by Phase, 2017
Figure 9: Number of CAR-T Clinical Trials & Completion Year, 2017
Figure 10:CAR T-cell Companies and Technologies, 2017

Table 1: CARs Generations-Associated Target Antigens and Indications
Table 2: CAR-T Cells Therapy - Company Collaborations and Deal Year, 2017
Table 3: CAR-T Cells Therapy - University Collaborations and Deal Year, 2017
Table 4: CAR-T Cells Therapy collaboration Deals and Values, 2017
Table 5: Companies CAR-T Investment for future developments, 2017
Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2017
Table 7:Companies open for licensing and collaborations, 2017
Table 8:Number of Products under Development, 2017
Table 9:Number of Products under Development by Companies, 2017
Table 10:Number of Products under Development by Indication, 2017
Table 11:Number of Products Targeting CD19 Antigen, 2017
Table 12:Number of Products Targeting Other Antigens, 2017
Table 13: Number of CAR-T Ongoing Clinical Trials & Completion Year, 2017
Table 14:CAR T-cell Companies and Technologies, 2017

Figure 1: Companies Collaborations vs. Financial year, 2017
Figure 2: Number of Companies Collaborations, 2017
Figure 3: Collaborations and Upfront Deal Values (In million, $), 2017
Figure 4: Number of Products under Development, 2017
Figure 5: Number of Products under Development by Companies, 2017
Figure 6: Number of Products under Development by Indication, 2017
Figure 7: CAR-T cell Targeted Antigens (%), 2017
Figure 8: Number of Products Targeting CD19 antigen by Phase, 2017
Figure 9: Number of CAR-T Clinical Trials & Completion Year, 2017
Figure 10:CAR T-cell Companies and Technologies, 2017

Table 1: CARs Generations-Associated Target Antigens and Indications
Table 2: CAR-T Cells Therapy - Company Collaborations and Deal Year, 2017
Table 3: CAR-T Cells Therapy - University Collaborations and Deal Year, 2017
Table 4: CAR-T Cells Therapy collaboration Deals and Values, 2017
Table 5: Companies CAR-T Investment for future developments, 2017
Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2017
Table 7:Companies open for licensing and collaborations, 2017
Table 8:Number of Products under Development, 2017
Table 9:Number of Products under Development by Companies, 2017
Table 10:Number of Products under Development by Indication, 2017
Table 11:Number of Products Targeting CD19 Antigen, 2017
Table 12:Number of Products Targeting Other Antigens, 2017
Table 13: Number of CAR-T Ongoing Clinical Trials & Completion Year, 2017
Table 14:CAR T-cell Companies and Technologies, 2017

Figure 1: Companies Collaborations vs. Financial year, 2017
Figure 2: Number of Companies Collaborations, 2017
Figure 3: Collaborations and Upfront Deal Values (In million, $), 2017
Figure 4: Number of Products under Development, 2017
Figure 5: Number of Products under Development by Companies, 2017
Figure 6: Number of Products under Development by Indication, 2017
Figure 7: CAR-T cell Targeted Antigens (%), 2017
Figure 8: Number of Products Targeting CD19 antigen by Phase, 2017
Figure 9: Number of CAR-T Clinical Trials & Completion Year, 2017
Figure 10:CAR T-cell Companies and Technologies, 2017

Table 1: CARs Generations-Associated Target Antigens and Indications
Table 2: CAR-T Cells Therapy - Company Collaborations and Deal Year, 2017
Table 3: CAR-T Cells Therapy - University Collaborations and Deal Year, 2017
Table 4: CAR-T Cells Therapy collaboration Deals and Values, 2017
Table 5: Companies CAR-T Investment for future developments, 2017
Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2017
Table 7:Companies open for licensing and collaborations, 2017
Table 8:Number of Products under Development, 2017
Table 9:Number of Products under Development by Companies, 2017
Table 10:Number of Products under Development by Indication, 2017
Table 11:Number of Products Targeting CD19 Antigen, 2017
Table 12:Number of Products Targeting Other Antigens, 2017
Table 13: Number of CAR-T Ongoing Clinical Trials & Completion Year, 2017
Table 14:CAR T-cell Companies and Technologies, 2017

Figure 1: Companies Collaborations vs. Financial year, 2017
Figure 2: Number of Companies Collaborations, 2017
Figure 3: Collaborations and Upfront Deal Values (In million, $), 2017
Figure 4: Number of Products under Development, 2017
Figure 5: Number of Products under Development by Companies, 2017
Figure 6: Number of Products under Development by Indication, 2017
Figure 7: CAR-T cell Targeted Antigens (%), 2017
Figure 8: Number of Products Targeting CD19 antigen by Phase, 2017
Figure 9: Number of CAR-T Clinical Trials & Completion Year, 2017
Figure 10:CAR T-cell Companies and Technologies, 2017

Table 1: CARs Generations-Associated Target Antigens and Indications
Table 2: CAR-T Cells Therapy - Company Collaborations and Deal Year, 2017
Table 3: CAR-T Cells Therapy - University Collaborations and Deal Year, 2017
Table 4: CAR-T Cells Therapy collaboration Deals and Values, 2017
Table 5: Companies CAR-T Investment for future developments, 2017
Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2017
Table 7:Companies open for licensing and collaborations, 2017
Table 8:Number of Products under Development, 2017
Table 9:Number of Products under Development by Companies, 2017
Table 10:Number of Products under Development by Indication, 2017
Table 11:Number of Products Targeting CD19 Antigen, 2017
Table 12:Number of Products Targeting Other Antigens, 2017
Table 13: Number of CAR-T Ongoing Clinical Trials & Completion Year, 2017
Table 14:CAR T-cell Companies and Technologies, 2017

Figure 1: Companies Collaborations vs. Financial year, 2017
Figure 2: Number of Companies Collaborations, 2017
Figure 3: Collaborations and Upfront Deal Values (In million, $), 2017
Figure 4: Number of Products under Development, 2017
Figure 5: Number of Products under Development by Companies, 2017
Figure 6: Number of Products under Development by Indication, 2017
Figure 7: CAR-T cell Targeted Antigens (%), 2017
Figure 8: Number of Products Targeting CD19 antigen by Phase, 2017
Figure 9: Number of CAR-T Clinical Trials & Completion Year, 2017
Figure 10:CAR T-cell Companies and Technologies, 2017

Table 1: CARs Generations-Associated Target Antigens and Indications
Table 2: CAR-T Cells Therapy - Company Collaborations and Deal Year, 2017
Table 3: CAR-T Cells Therapy - University Collaborations and Deal Year, 2017
Table 4: CAR-T Cells Therapy collaboration Deals and Values, 2017
Table 5: Companies CAR-T Investment for future developments, 2017
Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2017
Table 7:Companies open for licensing and collaborations, 2017
Table 8:Number of Products under Development, 2017
Table 9:Number of Products under Development by Companies, 2017
Table 10:Number of Products under Development by Indication, 2017
Table 11:Number of Products Targeting CD19 Antigen, 2017
Table 12:Number of Products Targeting Other Antigens, 2017
Table 13: Number of CAR-T Ongoing Clinical Trials & Completion Year, 2017
Table 14:CAR T-cell Companies and Technologies, 2017

Figure 1: Companies Collaborations vs. Financial year, 2017
Figure 2: Number of Companies Collaborations, 2017
Figure 3: Collaborations and Upfront Deal Values (In million, $), 2017
Figure 4: Number of Products under Development, 2017
Figure 5: Number of Products under Development by Companies, 2017
Figure 6: Number of Products under Development by Indication, 2017
Figure 7: CAR-T cell Targeted Antigens (%), 2017
Figure 8: Number of Products Targeting CD19 antigen by Phase, 2017
Figure 9: Number of CAR-T Clinical Trials & Completion Year, 2017
Figure 10:CAR T-cell Companies and Technologies, 2017

Table 1: CARs Generations-Associated Target Antigens and Indications
Table 2: CAR-T Cells Therapy - Company Collaborations and Deal Year, 2017
Table 3: CAR-T Cells Therapy - University Collaborations and Deal Year, 2017
Table 4: CAR-T Cells Therapy collaboration Deals and Values, 2017
Table 5: Companies CAR-T Investment for future developments, 2017
Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2017
Table 7:Companies open for licensing and collaborations, 2017
Table 8:Number of Products under Development, 2017
Table 9:Number of Products under Development by Companies, 2017
Table 10:Number of Products under Development by Indication, 2017
Table 11:Number of Products Targeting CD19 Antigen, 2017
Table 12:Number of Products Targeting Other Antigens, 2017
Table 13: Number of CAR-T Ongoing Clinical Trials & Completion Year, 2017
Table 14:CAR T-cell Companies and Technologies, 2017

Figure 1: Companies Collaborations vs. Financial year, 2017
Figure 2: Number of Companies Collaborations, 2017
Figure 3: Collaborations and Upfront Deal Values (In million, $), 2017
Figure 4: Number of Products under Development, 2017
Figure 5: Number of Products under Development by Companies, 2017
Figure 6: Number of Products under Development by Indication, 2017
Figure 7: CAR-T cell Targeted Antigens (%), 2017
Figure 8: Number of Products Targeting CD19 antigen by Phase, 2017
Figure 9: Number of CAR-T Clinical Trials & Completion Year, 2017
Figure 10:CAR T-cell Companies and Technologies, 2017

Table 1: CARs Generations-Associated Target Antigens and Indications
Table 2: CAR-T Cells Therapy - Company Collaborations and Deal Year, 2017
Table 3: CAR-T Cells Therapy - University Collaborations and Deal Year, 2017
Table 4: CAR-T Cells Therapy collaboration Deals and Values, 2017
Table 5: Companies CAR-T Investment for future developments, 2017
Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2017
Table 7:Companies open for licensing and collaborations, 2017
Table 8:Number of Products under Development, 2017
Table 9:Number of Products under Development by Companies, 2017
Table 10:Number of Products under Development by Indication, 2017
Table 11:Number of Products Targeting CD19 Antigen, 2017
Table 12:Number of Products Targeting Other Antigens, 2017
Table 13: Number of CAR-T Ongoing Clinical Trials & Completion Year, 2017
Table 14:CAR T-cell Companies and Technologies, 2017

Figure 1: Companies Collaborations vs. Financial year, 2017
Figure 2: Number of Companies Collaborations, 2017
Figure 3: Collaborations and Upfront Deal Values (In million, $), 2017
Figure 4: Number of Products under Development, 2017
Figure 5: Number of Products under Development by Companies, 2017
Figure 6: Number of Products under Development by Indication, 2017
Figure 7: CAR-T cell Targeted Antigens (%), 2017
Figure 8: Number of Products Targeting CD19 antigen by Phase, 2017
Figure 9: Number of CAR-T Clinical Trials & Completion Year, 2017
Figure 10:CAR T-cell Companies and Technologies, 2017

Table 1: CARs Generations-Associated Target Antigens and Indications
Table 2: CAR-T Cells Therapy - Company Collaborations and Deal Year, 2017
Table 3: CAR-T Cells Therapy - University Collaborations and Deal Year, 2017
Table 4: CAR-T Cells Therapy collaboration Deals and Values, 2017
Table 5: Companies CAR-T Investment for future developments, 2017
Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2017
Table 7:Companies open for licensing and collaborations, 2017
Table 8:Number of Products under Development, 2017
Table 9:Number of Products under Development by Companies, 2017
Table 10:Number of Products under Development by Indication, 2017
Table 11:Number of Products Targeting CD19 Antigen, 2017
Table 12:Number of Products Targeting Other Antigens, 2017
Table 13: Number of CAR-T Ongoing Clinical Trials & Completion Year, 2017
Table 14:CAR T-cell Companies and Technologies, 2017

Figure 1: Companies Collaborations vs. Financial year, 2017
Figure 2: Number of Companies Collaborations, 2017
Figure 3: Collaborations and Upfront Deal Values (In million, $), 2017
Figure 4: Number of Products under Development, 2017
Figure 5: Number of Products under Development by Companies, 2017
Figure 6: Number of Products under Development by Indication, 2017
Figure 7: CAR-T cell Targeted Antigens (%), 2017
Figure 8: Number of Products Targeting CD19 antigen by Phase, 2017
Figure 9: Number of CAR-T Clinical Trials & Completion Year, 2017
Figure 10:CAR T-cell Companies and Technologies, 2017

Table 1: CARs Generations-Associated Target Antigens and Indications
Table 2: CAR-T Cells Therapy - Company Collaborations and Deal Year, 2017
Table 3: CAR-T Cells Therapy - University Collaborations and Deal Year, 2017
Table 4: CAR-T Cells Therapy collaboration Deals and Values, 2017
Table 5: Companies CAR-T Investment for future developments, 2017
Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2017
Table 7:Companies open for licensing and collaborations, 2017
Table 8:Number of Products under Development, 2017
Table 9:Number of Products under Development by Companies, 2017
Table 10:Number of Products under Development by Indication, 2017
Table 11:Number of Products Targeting CD19 Antigen, 2017
Table 12:Number of Products Targeting Other Antigens, 2017
Table 13: Number of CAR-T Ongoing Clinical Trials & Completion Year, 2017
Table 14:CAR T-cell Companies and Technologies, 2017

Figure 1: Companies Collaborations vs. Financial year, 2017
Figure 2: Number of Companies Collaborations, 2017
Figure 3: Collaborations and Upfront Deal Values (In million, $), 2017
Figure 4: Number of Products under Development, 2017
Figure 5: Number of Products under Development by Companies, 2017
Figure 6: Number of Products under Development by Indication, 2017
Figure 7: CAR-T cell Targeted Antigens (%), 2017
Figure 8: Number of Products Targeting CD19 antigen by Phase, 2017
Figure 9: Number of CAR-T Clinical Trials & Completion Year, 2017
Figure 10:CAR T-cell Companies and Technologies, 2017

Table 1: CARs Generations-Associated Target Antigens and Indications
Table 2: CAR-T Cells Therapy - Company Collaborations and Deal Year, 2017
Table 3: CAR-T Cells Therapy - University Collaborations and Deal Year, 2017
Table 4: CAR-T Cells Therapy collaboration Deals and Values, 2017
Table 5: Companies CAR-T Investment for future developments, 2017
Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2017
Table 7:Companies open for licensing and collaborations, 2017
Table 8:Number of Products under Development, 2017
Table 9:Number of Products under Development by Companies, 2017
Table 10:Number of Products under Development by Indication, 2017
Table 11:Number of Products Targeting CD19 Antigen, 2017
Table 12:Number of Products Targeting Other Antigens, 2017
Table 13: Number of CAR-T Ongoing Clinical Trials & Completion Year, 2017
Table 14:CAR T-cell Companies and Technologies, 2017

Figure 1: Companies Collaborations vs. Financial year, 2017
Figure 2: Number of Companies Collaborations, 2017
Figure 3: Collaborations and Upfront Deal Values (In million, $), 2017
Figure 4: Number of Products under Development, 2017
Figure 5: Number of Products under Development by Companies, 2017
Figure 6: Number of Products under Development by Indication, 2017
Figure 7: CAR-T cell Targeted Antigens (%), 2017
Figure 8: Number of Products Targeting CD19 antigen by Phase, 2017
Figure 9: Number of CAR-T Clinical Trials & Completion Year, 2017
Figure 10:CAR T-cell Companies and Technologies, 2017

Table 1: CARs Generations-Associated Target Antigens and Indications
Table 2: CAR-T Cells Therapy - Company Collaborations and Deal Year, 2017
Table 3: CAR-T Cells Therapy - University Collaborations and Deal Year, 2017
Table 4: CAR-T Cells Therapy collaboration Deals and Values, 2017
Table 5: Companies CAR-T Investment for future developments, 2017
Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2017
Table 7:Companies open for licensing and collaborations, 2017
Table 8:Number of Products under Development, 2017
Table 9:Number of Products under Development by Companies, 2017
Table 10:Number of Products under Development by Indication, 2017
Table 11:Number of Products Targeting CD19 Antigen, 2017
Table 12:Number of Products Targeting Other Antigens, 2017
Table 13: Number of CAR-T Ongoing Clinical Trials & Completion Year, 2017
Table 14:CAR T-cell Companies and Technologies, 2017

Figure 1: Companies Collaborations vs. Financial year, 2017
Figure 2: Number of Companies Collaborations, 2017
Figure 3: Collaborations and Upfront Deal Values (In million, $), 2017
Figure 4: Number of Products under Development, 2017
Figure 5: Number of Products under Development by Companies, 2017
Figure 6: Number of Products under Development by Indication, 2017
Figure 7: CAR-T cell Targeted Antigens (%), 2017
Figure 8: Number of Products Targeting CD19 antigen by Phase, 2017
Figure 9: Number of CAR-T Clinical Trials & Completion Year, 2017
Figure 10:CAR T-cell Companies and Technologies, 2017

Table 1: CARs Generations-Associated Target Antigens and Indications
Table 2: CAR-T Cells Therapy - Company Collaborations and Deal Year, 2017
Table 3: CAR-T Cells Therapy - University Collaborations and Deal Year, 2017
Table 4: CAR-T Cells Therapy collaboration Deals and Values, 2017
Table 5: Companies CAR-T Investment for future developments, 2017
Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2017
Table 7:Companies open for licensing and collaborations, 2017
Table 8:Number of Products under Development, 2017
Table 9:Number of Products under Development by Companies, 2017
Table 10:Number of Products under Development by Indication, 2017
Table 11:Number of Products Targeting CD19 Antigen, 2017
Table 12:Number of Products Targeting Other Antigens, 2017
Table 13: Number of CAR-T Ongoing Clinical Trials & Completion Year, 2017
Table 14:CAR T-cell Companies and Technologies, 2017

Figure 1: Companies Collaborations vs. Financial year, 2017
Figure 2: Number of Companies Collaborations, 2017
Figure 3: Collaborations and Upfront Deal Values (In million, $), 2017
Figure 4: Number of Products under Development, 2017
Figure 5: Number of Products under Development by Companies, 2017
Figure 6: Number of Products under Development by Indication, 2017
Figure 7: CAR-T cell Targeted Antigens (%), 2017
Figure 8: Number of Products Targeting CD19 antigen by Phase, 2017
Figure 9: Number of CAR-T Clinical Trials & Completion Year, 2017
Figure 10:CAR T-cell Companies and Technologies, 2017

Table 1: CARs Generations-Associated Target Antigens and Indications
Table 2: CAR-T Cells Therapy - Company Collaborations and Deal Year, 2017
Table 3: CAR-T Cells Therapy - University Collaborations and Deal Year, 2017
Table 4: CAR-T Cells Therapy collaboration Deals and Values, 2017
Table 5: Companies CAR-T Investment for future developments, 2017
Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2017
Table 7:Companies open for licensing and collaborations, 2017
Table 8:Number of Products under Development, 2017
Table 9:Number of Products under Development by Companies, 2017
Table 10:Number of Products under Development by Indication, 2017
Table 11:Number of Products Targeting CD19 Antigen, 2017
Table 12:Number of Products Targeting Other Antigens, 2017
Table 13: Number of CAR-T Ongoing Clinical Trials & Completion Year, 2017
Table 14:CAR T-cell Companies and Technologies, 2017

Figure 1: Companies Collaborations vs. Financial year, 2017
Figure 2: Number of Companies Collaborations, 2017
Figure 3: Collaborations and Upfront Deal Values (In million, $), 2017
Figure 4: Number of Products under Development, 2017
Figure 5: Number of Products under Development by Companies, 2017
Figure 6: Number of Products under Development by Indication, 2017
Figure 7: CAR-T cell Targeted Antigens (%), 2017
Figure 8: Number of Products Targeting CD19 antigen by Phase, 2017
Figure 9: Number of CAR-T Clinical Trials & Completion Year, 2017
Figure 10:CAR T-cell Companies and Technologies, 2017

Table 1: CARs Generations-Associated Target Antigens and Indications
Table 2: CAR-T Cells Therapy - Company Collaborations and Deal Year, 2017
Table 3: CAR-T Cells Therapy - University Collaborations and Deal Year, 2017
Table 4: CAR-T Cells Therapy collaboration Deals and Values, 2017
Table 5: Companies CAR-T Investment for future developments, 2017
Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2017
Table 7:Companies open for licensing and collaborations, 2017
Table 8:Number of Products under Development, 2017
Table 9:Number of Products under Development by Companies, 2017
Table 10:Number of Products under Development by Indication, 2017
Table 11:Number of Products Targeting CD19 Antigen, 2017
Table 12:Number of Products Targeting Other Antigens, 2017
Table 13: Number of CAR-T Ongoing Clinical Trials & Completion Year, 2017
Table 14:CAR T-cell Companies and Technologies, 2017

Figure 1: Companies Collaborations vs. Financial year, 2017
Figure 2: Number of Companies Collaborations, 2017
Figure 3: Collaborations and Upfront Deal Values (In million, $), 2017
Figure 4: Number of Products under Development, 2017
Figure 5: Number of Products under Development by Companies, 2017
Figure 6: Number of Products under Development by Indication, 2017
Figure 7: CAR-T cell Targeted Antigens (%), 2017
Figure 8: Number of Products Targeting CD19 antigen by Phase, 2017
Figure 9: Number of CAR-T Clinical Trials & Completion Year, 2017
Figure 10:CAR T-cell Companies and Technologies, 2017

Table 1: CARs Generations-Associated Target Antigens and Indications
Table 2: CAR-T Cells Therapy - Company Collaborations and Deal Year, 2017
Table 3: CAR-T Cells Therapy - University Collaborations and Deal Year, 2017
Table 4: CAR-T Cells Therapy collaboration Deals and Values, 2017
Table 5: Companies CAR-T Investment for future developments, 2017
Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2017
Table 7:Companies open for licensing and collaborations, 2017
Table 8:Number of Products under Development, 2017
Table 9:Number of Products under Development by Companies, 2017
Table 10:Number of Products under Development by Indication, 2017
Table 11:Number of Products Targeting CD19 Antigen, 2017
Table 12:Number of Products Targeting Other Antigens, 2017
Table 13: Number of CAR-T Ongoing Clinical Trials & Completion Year, 2017
Table 14:CAR T-cell Companies and Technologies, 2017

Figure 1: Companies Collaborations vs. Financial year, 2017
Figure 2: Number of Companies Collaborations, 2017
Figure 3: Collaborations and Upfront Deal Values (In million, $), 2017
Figure 4: Number of Products under Development, 2017
Figure 5: Number of Products under Development by Companies, 2017
Figure 6: Number of Products under Development by Indication, 2017
Figure 7: CAR-T cell Targeted Antigens (%), 2017
Figure 8: Number of Products Targeting CD19 antigen by Phase, 2017
Figure 9: Number of CAR-T Clinical Trials & Completion Year, 2017
Figure 10:CAR T-cell Companies and Technologies, 2017

Table 1: CARs Generations-Associated Target Antigens and Indications
Table 2: CAR-T Cells Therapy - Company Collaborations and Deal Year, 2017
Table 3: CAR-T Cells Therapy - University Collaborations and Deal Year, 2017
Table 4: CAR-T Cells Therapy collaboration Deals and Values, 2017
Table 5: Companies CAR-T Investment for future developments, 2017
Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2017
Table 7:Companies open for licensing and collaborations, 2017
Table 8:Number of Products under Development, 2017
Table 9:Number of Products under Development by Companies, 2017
Table 10:Number of Products under Development by Indication, 2017
Table 11:Number of Products Targeting CD19 Antigen, 2017
Table 12:Number of Products Targeting Other Antigens, 2017
Table 13: Number of CAR-T Ongoing Clinical Trials & Completion Year, 2017
Table 14:CAR T-cell Companies and Technologies, 2017

Figure 1: Companies Collaborations vs. Financial year, 2017
Figure 2: Number of Companies Collaborations, 2017
Figure 3: Collaborations and Upfront Deal Values (In million, $), 2017
Figure 4: Number of Products under Development, 2017
Figure 5: Number of Products under Development by Companies, 2017
Figure 6: Number of Products under Development by Indication, 2017
Figure 7: CAR-T cell Targeted Antigens (%), 2017
Figure 8: Number of Products Targeting CD19 antigen by Phase, 2017
Figure 9: Number of CAR-T Clinical Trials & Completion Year, 2017
Figure 10:CAR T-cell Companies and Technologies, 2017

Table 1: CARs Generations-Associated Target Antigens and Indications
Table 2: CAR-T Cells Therapy - Company Collaborations and Deal Year, 2017
Table 3: CAR-T Cells Therapy - University Collaborations and Deal Year, 2017
Table 4: CAR-T Cells Therapy collaboration Deals and Values, 2017
Table 5: Companies CAR-T Investment for future developments, 2017
Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2017
Table 7:Companies open for licensing and collaborations, 2017
Table 8:Number of Products under Development, 2017
Table 9:Number of Products under Development by Companies, 2017
Table 10:Number of Products under Development by Indication, 2017
Table 11:Number of Products Targeting CD19 Antigen, 2017
Table 12:Number of Products Targeting Other Antigens, 2017
Table 13: Number of CAR-T Ongoing Clinical Trials & Completion Year, 2017
Table 14:CAR T-cell Companies and Technologies, 2017

Figure 1: Companies Collaborations vs. Financial year, 2017
Figure 2: Number of Companies Collaborations, 2017
Figure 3: Collaborations and Upfront Deal Values (In million, $), 2017
Figure 4: Number of Products under Development, 2017
Figure 5: Number of Products under Development by Companies, 2017
Figure 6: Number of Products under Development by Indication, 2017
Figure 7: CAR-T cell Targeted Antigens (%), 2017
Figure 8: Number of Products Targeting CD19 antigen by Phase, 2017
Figure 9: Number of CAR-T Clinical Trials & Completion Year, 2017
Figure 10:CAR T-cell Companies and Technologies, 2017

Table 1: CARs Generations-Associated Target Antigens and Indications
Table 2: CAR-T Cells Therapy - Company Collaborations and Deal Year, 2017
Table 3: CAR-T Cells Therapy - University Collaborations and Deal Year, 2017
Table 4: CAR-T Cells Therapy collaboration Deals and Values, 2017
Table 5: Companies CAR-T Investment for future developments, 2017
Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2017
Table 7:Companies open for licensing and collaborations, 2017
Table 8:Number of Products under Development, 2017
Table 9:Number of Products under Development by Companies, 2017
Table 10:Number of Products under Development by Indication, 2017
Table 11:Number of Products Targeting CD19 Antigen, 2017
Table 12:Number of Products Targeting Other Antigens, 2017
Table 13: Number of CAR-T Ongoing Clinical Trials & Completion Year, 2017
Table 14:CAR T-cell Companies and Technologies, 2017

Figure 1: Companies Collaborations vs. Financial year, 2017
Figure 2: Number of Companies Collaborations, 2017
Figure 3: Collaborations and Upfront Deal Values (In million, $), 2017
Figure 4: Number of Products under Development, 2017
Figure 5: Number of Products under Development by Companies, 2017
Figure 6: Number of Products under Development by Indication, 2017
Figure 7: CAR-T cell Targeted Antigens (%), 2017
Figure 8: Number of Products Targeting CD19 antigen by Phase, 2017
Figure 9: Number of CAR-T Clinical Trials & Completion Year, 2017
Figure 10:CAR T-cell Companies and Technologies, 2017

Table 1: CARs Generations-Associated Target Antigens and Indications
Table 2: CAR-T Cells Therapy - Company Collaborations and Deal Year, 2017
Table 3: CAR-T Cells Therapy - University Collaborations and Deal Year, 2017
Table 4: CAR-T Cells Therapy collaboration Deals and Values, 2017
Table 5: Companies CAR-T Investment for future developments, 2017
Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2017
Table 7:Companies open for licensing and collaborations, 2017
Table 8:Number of Products under Development, 2017
Table 9:Number of Products under Development by Companies, 2017
Table 10:Number of Products under Development by Indication, 2017
Table 11:Number of Products Targeting CD19 Antigen, 2017
Table 12:Number of Products Targeting Other Antigens, 2017
Table 13: Number of CAR-T Ongoing Clinical Trials & Completion Year, 2017
Table 14:CAR T-cell Companies and Technologies, 2017

Figure 1: Companies Collaborations vs. Financial year, 2017
Figure 2: Number of Companies Collaborations, 2017
Figure 3: Collaborations and Upfront Deal Values (In million, $), 2017
Figure 4: Number of Products under Development, 2017
Figure 5: Number of Products under Development by Companies, 2017
Figure 6: Number of Products under Development by Indication, 2017
Figure 7: CAR-T cell Targeted Antigens (%), 2017
Figure 8: Number of Products Targeting CD19 antigen by Phase, 2017
Figure 9: Number of CAR-T Clinical Trials & Completion Year, 2017
Figure 10:CAR T-cell Companies and Technologies, 2017

Table 1: CARs Generations-Associated Target Antigens and Indications
Table 2: CAR-T Cells Therapy - Company Collaborations and Deal Year, 2017
Table 3: CAR-T Cells Therapy - University Collaborations and Deal Year, 2017
Table 4: CAR-T Cells Therapy collaboration Deals and Values, 2017
Table 5: Companies CAR-T Investment for future developments, 2017
Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2017
Table 7:Companies open for licensing and collaborations, 2017
Table 8:Number of Products under Development, 2017
Table 9:Number of Products under Development by Companies, 2017
Table 10:Number of Products under Development by Indication, 2017
Table 11:Number of Products Targeting CD19 Antigen, 2017
Table 12:Number of Products Targeting Other Antigens, 2017
Table 13: Number of CAR-T Ongoing Clinical Trials & Completion Year, 2017
Table 14:CAR T-cell Companies and Technologies, 2017

Figure 1: Companies Collaborations vs. Financial year, 2017
Figure 2: Number of Companies Collaborations, 2017
Figure 3: Collaborations and Upfront Deal Values (In million, $), 2017
Figure 4: Number of Products under Development, 2017
Figure 5: Number of Products under Development by Companies, 2017
Figure 6: Number of Products under Development by Indication, 2017
Figure 7: CAR-T cell Targeted Antigens (%), 2017
Figure 8: Number of Products Targeting CD19 antigen by Phase, 2017
Figure 9: Number of CAR-T Clinical Trials & Completion Year, 2017
Figure 10:CAR T-cell Companies and Technologies, 2017

Table 1: CARs Generations-Associated Target Antigens and Indications
Table 2: CAR-T Cells Therapy - Company Collaborations and Deal Year, 2017
Table 3: CAR-T Cells Therapy - University Collaborations and Deal Year, 2017
Table 4: CAR-T Cells Therapy collaboration Deals and Values, 2017
Table 5: Companies CAR-T Investment for future developments, 2017
Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2017
Table 7:Companies open for licensing and collaborations, 2017
Table 8:Number of Products under Development, 2017
Table 9:Number of Products under Development by Companies, 2017
Table 10:Number of Products under Development by Indication, 2017
Table 11:Number of Products Targeting CD19 Antigen, 2017
Table 12:Number of Products Targeting Other Antigens, 2017
Table 13: Number of CAR-T Ongoing Clinical Trials & Completion Year, 2017
Table 14:CAR T-cell Companies and Technologies, 2017

Figure 1: Companies Collaborations vs. Financial year, 2017
Figure 2: Number of Companies Collaborations, 2017
Figure 3: Collaborations and Upfront Deal Values (In million, $), 2017
Figure 4: Number of Products under Development, 2017
Figure 5: Number of Products under Development by Companies, 2017
Figure 6: Number of Products under Development by Indication, 2017
Figure 7: CAR-T cell Targeted Antigens (%), 2017
Figure 8: Number of Products Targeting CD19 antigen by Phase, 2017
Figure 9: Number of CAR-T Clinical Trials & Completion Year, 2017
Figure 10:CAR T-cell Companies and Technologies, 2017

Table 1: CARs Generations-Associated Target Antigens and Indications
Table 2: CAR-T Cells Therapy - Company Collaborations and Deal Year, 2017
Table 3: CAR-T Cells Therapy - University Collaborations and Deal Year, 2017
Table 4: CAR-T Cells Therapy collaboration Deals and Values, 2017
Table 5: Companies CAR-T Investment for future developments, 2017
Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2017
Table 7:Companies open for licensing and collaborations, 2017
Table 8:Number of Products under Development, 2017
Table 9:Number of Products under Development by Companies, 2017
Table 10:Number of Products under Development by Indication, 2017
Table 11:Number of Products Targeting CD19 Antigen, 2017
Table 12:Number of Products Targeting Other Antigens, 2017
Table 13: Number of CAR-T Ongoing Clinical Trials & Completion Year, 2017
Table 14:CAR T-cell Companies and Technologies, 2017

Figure 1: Companies Collaborations vs. Financial year, 2017
Figure 2: Number of Companies Collaborations, 2017
Figure 3: Collaborations and Upfront Deal Values (In million, $), 2017
Figure 4: Number of Products under Development, 2017
Figure 5: Number of Products under Development by Companies, 2017
Figure 6: Number of Products under Development by Indication, 2017
Figure 7: CAR-T cell Targeted Antigens (%), 2017
Figure 8: Number of Products Targeting CD19 antigen by Phase, 2017
Figure 9: Number of CAR-T Clinical Trials & Completion Year, 2017
Figure 10:CAR T-cell Companies and Technologies, 2017

Table 1: CARs Generations-Associated Target Antigens and Indications
Table 2: CAR-T Cells Therapy - Company Collaborations and Deal Year, 2017
Table 3: CAR-T Cells Therapy - University Collaborations and Deal Year, 2017
Table 4: CAR-T Cells Therapy collaboration Deals and Values, 2017
Table 5: Companies CAR-T Investment for future developments, 2017
Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2017
Table 7:Companies open for licensing and collaborations, 2017
Table 8:Number of Products under Development, 2017
Table 9:Number of Products under Development by Companies, 2017
Table 10:Number of Products under Development by Indication, 2017
Table 11:Number of Products Targeting CD19 Antigen, 2017
Table 12:Number of Products Targeting Other Antigens, 2017
Table 13: Number of CAR-T Ongoing Clinical Trials & Completion Year, 2017
Table 14:CAR T-cell Companies and Technologies, 2017

Figure 1: Companies Collaborations vs. Financial year, 2017
Figure 2: Number of Companies Collaborations, 2017
Figure 3: Collaborations and Upfront Deal Values (In million, $), 2017
Figure 4: Number of Products under Development, 2017
Figure 5: Number of Products under Development by Companies, 2017
Figure 6: Number of Products under Development by Indication, 2017
Figure 7: CAR-T cell Targeted Antigens (%), 2017
Figure 8: Number of Products Targeting CD19 antigen by Phase, 2017
Figure 9: Number of CAR-T Clinical Trials & Completion Year, 2017
Figure 10:CAR T-cell Companies and Technologies, 2017

Table 1: CARs Generations-Associated Target Antigens and Indications
Table 2: CAR-T Cells Therapy - Company Collaborations and Deal Year, 2017
Table 3: CAR-T Cells Therapy - University Collaborations and Deal Year, 2017
Table 4: CAR-T Cells Therapy collaboration Deals and Values, 2017
Table 5: Companies CAR-T Investment for future developments, 2017
Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2017
Table 7:Companies open for licensing and collaborations, 2017
Table 8:Number of Products under Development, 2017
Table 9:Number of Products under Development by Companies, 2017
Table 10:Number of Products under Development by Indication, 2017
Table 11:Number of Products Targeting CD19 Antigen, 2017
Table 12:Number of Products Targeting Other Antigens, 2017
Table 13: Number of CAR-T Ongoing Clinical Trials & Completion Year, 2017
Table 14:CAR T-cell Companies and Technologies, 2017

Figure 1: Companies Collaborations vs. Financial year, 2017
Figure 2: Number of Companies Collaborations, 2017
Figure 3: Collaborations and Upfront Deal Values (In million, $), 2017
Figure 4: Number of Products under Development, 2017
Figure 5: Number of Products under Development by Companies, 2017
Figure 6: Number of Products under Development by Indication, 2017
Figure 7: CAR-T cell Targeted Antigens (%), 2017
Figure 8: Number of Products Targeting CD19 antigen by Phase, 2017
Figure 9: Number of CAR-T Clinical Trials & Completion Year, 2017
Figure 10:CAR T-cell Companies and Technologies, 2017

Table 1: CARs Generations-Associated Target Antigens and Indications
Table 2: CAR-T Cells Therapy - Company Collaborations and Deal Year, 2017
Table 3: CAR-T Cells Therapy - University Collaborations and Deal Year, 2017
Table 4: CAR-T Cells Therapy collaboration Deals and Values, 2017
Table 5: Companies CAR-T Investment for future developments, 2017
Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2017
Table 7:Companies open for licensing and collaborations, 2017
Table 8:Number of Products under Development, 2017
Table 9:Number of Products under Development by Companies, 2017
Table 10:Number of Products under Development by Indication, 2017
Table 11:Number of Products Targeting CD19 Antigen, 2017
Table 12:Number of Products Targeting Other Antigens, 2017
Table 13: Number of CAR-T Ongoing Clinical Trials & Completion Year, 2017
Table 14:CAR T-cell Companies and Technologies, 2017

Figure 1: Companies Collaborations vs. Financial year, 2017
Figure 2: Number of Companies Collaborations, 2017
Figure 3: Collaborations and Upfront Deal Values (In million, $), 2017
Figure 4: Number of Products under Development, 2017
Figure 5: Number of Products under Development by Companies, 2017
Figure 6: Number of Products under Development by Indication, 2017
Figure 7: CAR-T cell Targeted Antigens (%), 2017
Figure 8: Number of Products Targeting CD19 antigen by Phase, 2017
Figure 9: Number of CAR-T Clinical Trials & Completion Year, 2017
Figure 10:CAR T-cell Companies and Technologies, 2017

Table 1: CARs Generations-Associated Target Antigens and Indications
Table 2: CAR-T Cells Therapy - Company Collaborations and Deal Year, 2017
Table 3: CAR-T Cells Therapy - University Collaborations and Deal Year, 2017
Table 4: CAR-T Cells Therapy collaboration Deals and Values, 2017
Table 5: Companies CAR-T Investment for future developments, 2017
Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2017
Table 7:Companies open for licensing and collaborations, 2017
Table 8:Number of Products under Development, 2017
Table 9:Number of Products under Development by Companies, 2017
Table 10:Number of Products under Development by Indication, 2017
Table 11:Number of Products Targeting CD19 Antigen, 2017
Table 12:Number of Products Targeting Other Antigens, 2017
Table 13: Number of CAR-T Ongoing Clinical Trials & Completion Year, 2017
Table 14:CAR T-cell Companies and Technologies, 2017

Figure 1: Companies Collaborations vs. Financial year, 2017
Figure 2: Number of Companies Collaborations, 2017
Figure 3: Collaborations and Upfront Deal Values (In million, $), 2017
Figure 4: Number of Products under Development, 2017
Figure 5: Number of Products under Development by Companies, 2017
Figure 6: Number of Products under Development by Indication, 2017
Figure 7: CAR-T cell Targeted Antigens (%), 2017
Figure 8: Number of Products Targeting CD19 antigen by Phase, 2017
Figure 9: Number of CAR-T Clinical Trials & Completion Year, 2017
Figure 10:CAR T-cell Companies and Technologies, 2017

Table 1: CARs Generations-Associated Target Antigens and Indications
Table 2: CAR-T Cells Therapy - Company Collaborations and Deal Year, 2017
Table 3: CAR-T Cells Therapy - University Collaborations and Deal Year, 2017
Table 4: CAR-T Cells Therapy collaboration Deals and Values, 2017
Table 5: Companies CAR-T Investment for future developments, 2017
Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2017
Table 7:Companies open for licensing and collaborations, 2017
Table 8:Number of Products under Development, 2017
Table 9:Number of Products under Development by Companies, 2017
Table 10:Number of Products under Development by Indication, 2017
Table 11:Number of Products Targeting CD19 Antigen, 2017
Table 12:Number of Products Targeting Other Antigens, 2017
Table 13: Number of CAR-T Ongoing Clinical Trials & Completion Year, 2017
Table 14:CAR T-cell Companies and Technologies, 2017

Figure 1: Companies Collaborations vs. Financial year, 2017
Figure 2: Number of Companies Collaborations, 2017
Figure 3: Collaborations and Upfront Deal Values (In million, $), 2017
Figure 4: Number of Products under Development, 2017
Figure 5: Number of Products under Development by Companies, 2017
Figure 6: Number of Products under Development by Indication, 2017
Figure 7: CAR-T cell Targeted Antigens (%), 2017
Figure 8: Number of Products Targeting CD19 antigen by Phase, 2017
Figure 9: Number of CAR-T Clinical Trials & Completion Year, 2017
Figure 10:CAR T-cell Companies and Technologies, 2017

Table 1: CARs Generations-Associated Target Antigens and Indications
Table 2: CAR-T Cells Therapy - Company Collaborations and Deal Year, 2017
Table 3: CAR-T Cells Therapy - University Collaborations and Deal Year, 2017
Table 4: CAR-T Cells Therapy collaboration Deals and Values, 2017
Table 5: Companies CAR-T Investment for future developments, 2017
Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2017
Table 7:Companies open for licensing and collaborations, 2017
Table 8:Number of Products under Development, 2017
Table 9:Number of Products under Development by Companies, 2017
Table 10:Number of Products under Development by Indication, 2017
Table 11:Number of Products Targeting CD19 Antigen, 2017
Table 12:Number of Products Targeting Other Antigens, 2017
Table 13: Number of CAR-T Ongoing Clinical Trials & Completion Year, 2017
Table 14:CAR T-cell Companies and Technologies, 2017

Figure 1: Companies Collaborations vs. Financial year, 2017
Figure 2: Number of Companies Collaborations, 2017
Figure 3: Collaborations and Upfront Deal Values (In million, $), 2017
Figure 4: Number of Products under Development, 2017
Figure 5: Number of Products under Development by Companies, 2017
Figure 6: Number of Products under Development by Indication, 2017
Figure 7: CAR-T cell Targeted Antigens (%), 2017
Figure 8: Number of Products Targeting CD19 antigen by Phase, 2017
Figure 9: Number of CAR-T Clinical Trials & Completion Year, 2017
Figure 10:CAR T-cell Companies and Technologies, 2017

Table 1: CARs Generations-Associated Target Antigens and Indications
Table 2: CAR-T Cells Therapy - Company Collaborations and Deal Year, 2017
Table 3: CAR-T Cells Therapy - University Collaborations and Deal Year, 2017
Table 4: CAR-T Cells Therapy collaboration Deals and Values, 2017
Table 5: Companies CAR-T Investment for future developments, 2017
Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2017
Table 7:Companies open for licensing and collaborations, 2017
Table 8:Number of Products under Development, 2017
Table 9:Number of Products under Development by Companies, 2017
Table 10:Number of Products under Development by Indication, 2017
Table 11:Number of Products Targeting CD19 Antigen, 2017
Table 12:Number of Products Targeting Other Antigens, 2017
Table 13: Number of CAR-T Ongoing Clinical Trials & Completion Year, 2017
Table 14:CAR T-cell Companies and Technologies, 2017

Figure 1: Companies Collaborations vs. Financial year, 2017
Figure 2: Number of Companies Collaborations, 2017
Figure 3: Collaborations and Upfront Deal Values (In million, $), 2017
Figure 4: Number of Products under Development, 2017
Figure 5: Number of Products under Development by Companies, 2017
Figure 6: Number of Products under Development by Indication, 2017
Figure 7: CAR-T cell Targeted Antigens (%), 2017
Figure 8: Number of Products Targeting CD19 antigen by Phase, 2017
Figure 9: Number of CAR-T Clinical Trials & Completion Year, 2017
Figure 10:CAR T-cell Companies and Technologies, 2017

Table 1: CARs Generations-Associated Target Antigens and Indications
Table 2: CAR-T Cells Therapy - Company Collaborations and Deal Year, 2017
Table 3: CAR-T Cells Therapy - University Collaborations and Deal Year, 2017
Table 4: CAR-T Cells Therapy collaboration Deals and Values, 2017
Table 5: Companies CAR-T Investment for future developments, 2017
Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2017
Table 7:Companies open for licensing and collaborations, 2017
Table 8:Number of Products under Development, 2017
Table 9:Number of Products under Development by Companies, 2017
Table 10:Number of Products under Development by Indication, 2017
Table 11:Number of Products Targeting CD19 Antigen, 2017
Table 12:Number of Products Targeting Other Antigens, 2017
Table 13: Number of CAR-T Ongoing Clinical Trials & Completion Year, 2017
Table 14:CAR T-cell Companies and Technologies, 2017

Figure 1: Companies Collaborations vs. Financial year, 2017
Figure 2: Number of Companies Collaborations, 2017
Figure 3: Collaborations and Upfront Deal Values (In million, $), 2017
Figure 4: Number of Products under Development, 2017
Figure 5: Number of Products under Development by Companies, 2017
Figure 6: Number of Products under Development by Indication, 2017
Figure 7: CAR-T cell Targeted Antigens (%), 2017
Figure 8: Number of Products Targeting CD19 antigen by Phase, 2017
Figure 9: Number of CAR-T Clinical Trials & Completion Year, 2017
Figure 10:CAR T-cell Companies and Technologies, 2017

Table 1: CARs Generations-Associated Target Antigens and Indications
Table 2: CAR-T Cells Therapy - Company Collaborations and Deal Year, 2017
Table 3: CAR-T Cells Therapy - University Collaborations and Deal Year, 2017
Table 4: CAR-T Cells Therapy collaboration Deals and Values, 2017
Table 5: Companies CAR-T Investment for future developments, 2017
Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2017
Table 7:Companies open for licensing and collaborations, 2017
Table 8:Number of Products under Development, 2017
Table 9:Number of Products under Development by Companies, 2017
Table 10:Number of Products under Development by Indication, 2017
Table 11:Number of Products Targeting CD19 Antigen, 2017
Table 12:Number of Products Targeting Other Antigens, 2017
Table 13: Number of CAR-T Ongoing Clinical Trials & Completion Year, 2017
Table 14:CAR T-cell Companies and Technologies, 2017

Figure 1: Companies Collaborations vs. Financial year, 2017
Figure 2: Number of Companies Collaborations, 2017
Figure 3: Collaborations and Upfront Deal Values (In million, $), 2017
Figure 4: Number of Products under Development, 2017
Figure 5: Number of Products under Development by Companies, 2017
Figure 6: Number of Products under Development by Indication, 2017
Figure 7: CAR-T cell Targeted Antigens (%), 2017
Figure 8: Number of Products Targeting CD19 antigen by Phase, 2017
Figure 9: Number of CAR-T Clinical Trials & Completion Year, 2017
Figure 10:CAR T-cell Companies and Technologies, 2017

Table 1: CARs Generations-Associated Target Antigens and Indications
Table 2: CAR-T Cells Therapy - Company Collaborations and Deal Year, 2017
Table 3: CAR-T Cells Therapy - University Collaborations and Deal Year, 2017
Table 4: CAR-T Cells Therapy collaboration Deals and Values, 2017
Table 5: Companies CAR-T Investment for future developments, 2017
Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2017
Table 7:Companies open for licensing and collaborations, 2017
Table 8:Number of Products under Development, 2017
Table 9:Number of Products under Development by Companies, 2017
Table 10:Number of Products under Development by Indication, 2017
Table 11:Number of Products Targeting CD19 Antigen, 2017
Table 12:Number of Products Targeting Other Antigens, 2017
Table 13: Number of CAR-T Ongoing Clinical Trials & Completion Year, 2017
Table 14:CAR T-cell Companies and Technologies, 2017

Figure 1: Companies Collaborations vs. Financial year, 2017
Figure 2: Number of Companies Collaborations, 2017
Figure 3: Collaborations and Upfront Deal Values (In million, $), 2017
Figure 4: Number of Products under Development, 2017
Figure 5: Number of Products under Development by Companies, 2017
Figure 6: Number of Products under Development by Indication, 2017
Figure 7: CAR-T cell Targeted Antigens (%), 2017
Figure 8: Number of Products Targeting CD19 antigen by Phase, 2017
Figure 9: Number of CAR-T Clinical Trials & Completion Year, 2017
Figure 10:CAR T-cell Companies and Technologies, 2017

Table 1: CARs Generations-Associated Target Antigens and Indications
Table 2: CAR-T Cells Therapy - Company Collaborations and Deal Year, 2017
Table 3: CAR-T Cells Therapy - University Collaborations and Deal Year, 2017
Table 4: CAR-T Cells Therapy collaboration Deals and Values, 2017
Table 5: Companies CAR-T Investment for future developments, 2017
Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2017
Table 7:Companies open for licensing and collaborations, 2017
Table 8:Number of Products under Development, 2017
Table 9:Number of Products under Development by Companies, 2017
Table 10:Number of Products under Development by Indication, 2017
Table 11:Number of Products Targeting CD19 Antigen, 2017
Table 12:Number of Products Targeting Other Antigens, 2017
Table 13: Number of CAR-T Ongoing Clinical Trials & Completion Year, 2017
Table 14:CAR T-cell Companies and Technologies, 2017

Figure 1: Companies Collaborations vs. Financial year, 2017
Figure 2: Number of Companies Collaborations, 2017
Figure 3: Collaborations and Upfront Deal Values (In million, $), 2017
Figure 4: Number of Products under Development, 2017
Figure 5: Number of Products under Development by Companies, 2017
Figure 6: Number of Products under Development by Indication, 2017
Figure 7: CAR-T cell Targeted Antigens (%), 2017
Figure 8: Number of Products Targeting CD19 antigen by Phase, 2017
Figure 9: Number of CAR-T Clinical Trials & Completion Year, 2017
Figure 10:CAR T-cell Companies and Technologies, 2017

Table 1: CARs Generations-Associated Target Antigens and Indications
Table 2: CAR-T Cells Therapy - Company Collaborations and Deal Year, 2017
Table 3: CAR-T Cells Therapy - University Collaborations and Deal Year, 2017
Table 4: CAR-T Cells Therapy collaboration Deals and Values, 2017
Table 5: Companies CAR-T Investment for future developments, 2017
Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2017
Table 7:Companies open for licensing and collaborations, 2017
Table 8:Number of Products under Development, 2017
Table 9:Number of Products under Development by Companies, 2017
Table 10:Number of Products under Development by Indication, 2017
Table 11:Number of Products Targeting CD19 Antigen, 2017
Table 12:Number of Products Targeting Other Antigens, 2017
Table 13: Number of CAR-T Ongoing Clinical Trials & Completion Year, 2017
Table 14:CAR T-cell Companies and Technologies, 2017

Figure 1: Companies Collaborations vs. Financial year, 2017
Figure 2: Number of Companies Collaborations, 2017
Figure 3: Collaborations and Upfront Deal Values (In million, $), 2017
Figure 4: Number of Products under Development, 2017
Figure 5: Number of Products under Development by Companies, 2017
Figure 6: Number of Products under Development by Indication, 2017
Figure 7: CAR-T cell Targeted Antigens (%), 2017
Figure 8: Number of Products Targeting CD19 antigen by Phase, 2017
Figure 9: Number of CAR-T Clinical Trials & Completion Year, 2017
Figure 10:CAR T-cell Companies and Technologies, 2017

Table 1: CARs Generations-Associated Target Antigens and Indications
Table 2: CAR-T Cells Therapy - Company Collaborations and Deal Year, 2017
Table 3: CAR-T Cells Therapy - University Collaborations and Deal Year, 2017
Table 4: CAR-T Cells Therapy collaboration Deals and Values, 2017
Table 5: Companies CAR-T Investment for future developments, 2017
Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2017
Table 7:Companies open for licensing and collaborations, 2017
Table 8:Number of Products under Development, 2017
Table 9:Number of Products under Development by Companies, 2017
Table 10:Number of Products under Development by Indication, 2017
Table 11:Number of Products Targeting CD19 Antigen, 2017
Table 12:Number of Products Targeting Other Antigens, 2017
Table 13: Number of CAR-T Ongoing Clinical Trials & Completion Year, 2017
Table 14:CAR T-cell Companies and Technologies, 2017

Figure 1: Companies Collaborations vs. Financial year, 2017
Figure 2: Number of Companies Collaborations, 2017
Figure 3: Collaborations and Upfront Deal Values (In million, $), 2017
Figure 4: Number of Products under Development, 2017
Figure 5: Number of Products under Development by Companies, 2017
Figure 6: Number of Products under Development by Indication, 2017
Figure 7: CAR-T cell Targeted Antigens (%), 2017
Figure 8: Number of Products Targeting CD19 antigen by Phase, 2017
Figure 9: Number of CAR-T Clinical Trials & Completion Year, 2017
Figure 10:CAR T-cell Companies and Technologies, 2017

Table 1: CARs Generations-Associated Target Antigens and Indications
Table 2: CAR-T Cells Therapy - Company Collaborations and Deal Year, 2017
Table 3: CAR-T Cells Therapy - University Collaborations and Deal Year, 2017
Table 4: CAR-T Cells Therapy collaboration Deals and Values, 2017
Table 5: Companies CAR-T Investment for future developments, 2017
Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2017
Table 7:Companies open for licensing and collaborations, 2017
Table 8:Number of Products under Development, 2017
Table 9:Number of Products under Development by Companies, 2017
Table 10:Number of Products under Development by Indication, 2017
Table 11:Number of Products Targeting CD19 Antigen, 2017
Table 12:Number of Products Targeting Other Antigens, 2017
Table 13: Number of CAR-T Ongoing Clinical Trials & Completion Year, 2017
Table 14:CAR T-cell Companies and Technologies, 2017

Figure 1: Companies Collaborations vs. Financial year, 2017
Figure 2: Number of Companies Collaborations, 2017
Figure 3: Collaborations and Upfront Deal Values (In million, $), 2017
Figure 4: Number of Products under Development, 2017
Figure 5: Number of Products under Development by Companies, 2017
Figure 6: Number of Products under Development by Indication, 2017
Figure 7: CAR-T cell Targeted Antigens (%), 2017
Figure 8: Number of Products Targeting CD19 antigen by Phase, 2017
Figure 9: Number of CAR-T Clinical Trials & Completion Year, 2017
Figure 10:CAR T-cell Companies and Technologies, 2017

Table 1: CARs Generations-Associated Target Antigens and Indications
Table 2: CAR-T Cells Therapy - Company Collaborations and Deal Year, 2017
Table 3: CAR-T Cells Therapy - University Collaborations and Deal Year, 2017
Table 4: CAR-T Cells Therapy collaboration Deals and Values, 2017
Table 5: Companies CAR-T Investment for future developments, 2017
Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2017
Table 7:Companies open for licensing and collaborations, 2017
Table 8:Number of Products under Development, 2017
Table 9:Number of Products under Development by Companies, 2017
Table 10:Number of Products under Development by Indication, 2017
Table 11:Number of Products Targeting CD19 Antigen, 2017
Table 12:Number of Products Targeting Other Antigens, 2017
Table 13: Number of CAR-T Ongoing Clinical Trials & Completion Year, 2017
Table 14:CAR T-cell Companies and Technologies, 2017

Figure 1: Companies Collaborations vs. Financial year, 2017
Figure 2: Number of Companies Collaborations, 2017
Figure 3: Collaborations and Upfront Deal Values (In million, $), 2017
Figure 4: Number of Products under Development, 2017
Figure 5: Number of Products under Development by Companies, 2017
Figure 6: Number of Products under Development by Indication, 2017
Figure 7: CAR-T cell Targeted Antigens (%), 2017
Figure 8: Number of Products Targeting CD19 antigen by Phase, 2017
Figure 9: Number of CAR-T Clinical Trials & Completion Year, 2017
Figure 10:CAR T-cell Companies and Technologies, 2017

Table 1: CARs Generations-Associated Target Antigens and Indications
Table 2: CAR-T Cells Therapy - Company Collaborations and Deal Year, 2017
Table 3: CAR-T Cells Therapy - University Collaborations and Deal Year, 2017
Table 4: CAR-T Cells Therapy collaboration Deals and Values, 2017
Table 5: Companies CAR-T Investment for future developments, 2017
Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2017
Table 7:Companies open for licensing and collaborations, 2017
Table 8:Number of Products under Development, 2017
Table 9:Number of Products under Development by Companies, 2017
Table 10:Number of Products under Development by Indication, 2017
Table 11:Number of Products Targeting CD19 Antigen, 2017
Table 12:Number of Products Targeting Other Antigens, 2017
Table 13: Number of CAR-T Ongoing Clinical Trials & Completion Year, 2017
Table 14:CAR T-cell Companies and Technologies, 2017

Figure 1: Companies Collaborations vs. Financial year, 2017
Figure 2: Number of Companies Collaborations, 2017
Figure 3: Collaborations and Upfront Deal Values (In million, $), 2017
Figure 4: Number of Products under Development, 2017
Figure 5: Number of Products under Development by Companies, 2017
Figure 6: Number of Products under Development by Indication, 2017
Figure 7: CAR-T cell Targeted Antigens (%), 2017
Figure 8: Number of Products Targeting CD19 antigen by Phase, 2017
Figure 9: Number of CAR-T Clinical Trials & Completion Year, 2017
Figure 10:CAR T-cell Companies and Technologies, 2017

Table 1: CARs Generations-Associated Target Antigens and Indications
Table 2: CAR-T Cells Therapy - Company Collaborations and Deal Year, 2017
Table 3: CAR-T Cells Therapy - University Collaborations and Deal Year, 2017
Table 4: CAR-T Cells Therapy collaboration Deals and Values, 2017
Table 5: Companies CAR-T Investment for future developments, 2017
Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2017
Table 7:Companies open for licensing and collaborations, 2017
Table 8:Number of Products under Development, 2017
Table 9:Number of Products under Development by Companies, 2017
Table 10:Number of Products under Development by Indication, 2017
Table 11:Number of Products Targeting CD19 Antigen, 2017
Table 12:Number of Products Targeting Other Antigens, 2017
Table 13: Number of CAR-T Ongoing Clinical Trials & Completion Year, 2017
Table 14:CAR T-cell Companies and Technologies, 2017

Figure 1: Companies Collaborations vs. Financial year, 2017
Figure 2: Number of Companies Collaborations, 2017
Figure 3: Collaborations and Upfront Deal Values (In million, $), 2017
Figure 4: Number of Products under Development, 2017
Figure 5: Number of Products under Development by Companies, 2017
Figure 6: Number of Products under Development by Indication, 2017
Figure 7: CAR-T cell Targeted Antigens (%), 2017
Figure 8: Number of Products Targeting CD19 antigen by Phase, 2017
Figure 9: Number of CAR-T Clinical Trials & Completion Year, 2017
Figure 10:CAR T-cell Companies and Technologies, 2017

Table 1: CARs Generations-Associated Target Antigens and Indications
Table 2: CAR-T Cells Therapy - Company Collaborations and Deal Year, 2017
Table 3: CAR-T Cells Therapy - University Collaborations and Deal Year, 2017
Table 4: CAR-T Cells Therapy collaboration Deals and Values, 2017
Table 5: Companies CAR-T Investment for future developments, 2017
Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2017
Table 7:Companies open for licensing and collaborations, 2017
Table 8:Number of Products under Development, 2017
Table 9:Number of Products under Development by Companies, 2017
Table 10:Number of Products under Development by Indication, 2017
Table 11:Number of Products Targeting CD19 Antigen, 2017
Table 12:Number of Products Targeting Other Antigens, 2017
Table 13: Number of CAR-T Ongoing Clinical Trials & Completion Year, 2017
Table 14:CAR T-cell Companies and Technologies, 2017

Figure 1: Companies Collaborations vs. Financial year, 2017
Figure 2: Number of Companies Collaborations, 2017
Figure 3: Collaborations and Upfront Deal Values (In million, $), 2017
Figure 4: Number of Products under Development, 2017
Figure 5: Number of Products under Development by Companies, 2017
Figure 6: Number of Products under Development by Indication, 2017
Figure 7: CAR-T cell Targeted Antigens (%), 2017
Figure 8: Number of Products Targeting CD19 antigen by Phase, 2017
Figure 9: Number of CAR-T Clinical Trials & Completion Year, 2017
Figure 10:CAR T-cell Companies and Technologies, 2017

Table 1: CARs Generations-Associated Target Antigens and Indications
Table 2: CAR-T Cells Therapy - Company Collaborations and Deal Year, 2017
Table 3: CAR-T Cells Therapy - University Collaborations and Deal Year, 2017
Table 4: CAR-T Cells Therapy collaboration Deals and Values, 2017
Table 5: Companies CAR-T Investment for future developments, 2017
Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2017
Table 7:Companies open for licensing and collaborations, 2017
Table 8:Number of Products under Development, 2017
Table 9:Number of Products under Development by Companies, 2017
Table 10:Number of Products under Development by Indication, 2017
Table 11:Number of Products Targeting CD19 Antigen, 2017
Table 12:Number of Products Targeting Other Antigens, 2017
Table 13: Number of CAR-T Ongoing Clinical Trials & Completion Year, 2017
Table 14:CAR T-cell Companies and Technologies, 2017

Figure 1: Companies Collaborations vs. Financial year, 2017
Figure 2: Number of Companies Collaborations, 2017
Figure 3: Collaborations and Upfront Deal Values (In million, $), 2017
Figure 4: Number of Products under Development, 2017
Figure 5: Number of Products under Development by Companies, 2017
Figure 6: Number of Products under Development by Indication, 2017
Figure 7: CAR-T cell Targeted Antigens (%), 2017
Figure 8: Number of Products Targeting CD19 antigen by Phase, 2017
Figure 9: Number of CAR-T Clinical Trials & Completion Year, 2017
Figure 10:CAR T-cell Companies and Technologies, 2017

Table 1: CARs Generations-Associated Target Antigens and Indications
Table 2: CAR-T Cells Therapy - Company Collaborations and Deal Year, 2017
Table 3: CAR-T Cells Therapy - University Collaborations and Deal Year, 2017
Table 4: CAR-T Cells Therapy collaboration Deals and Values, 2017
Table 5: Companies CAR-T Investment for future developments, 2017
Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2017
Table 7:Companies open for licensing and collaborations, 2017
Table 8:Number of Products under Development, 2017
Table 9:Number of Products under Development by Companies, 2017
Table 10:Number of Products under Development by Indication, 2017
Table 11:Number of Products Targeting CD19 Antigen, 2017
Table 12:Number of Products Targeting Other Antigens, 2017
Table 13: Number of CAR-T Ongoing Clinical Trials & Completion Year, 2017
Table 14:CAR T-cell Companies and Technologies, 2017

Figure 1: Companies Collaborations vs. Financial year, 2017
Figure 2: Number of Companies Collaborations, 2017
Figure 3: Collaborations and Upfront Deal Values (In million, $), 2017
Figure 4: Number of Products under Development, 2017
Figure 5: Number of Products under Development by Companies, 2017
Figure 6: Number of Products under Development by Indication, 2017
Figure 7: CAR-T cell Targeted Antigens (%), 2017
Figure 8: Number of Products Targeting CD19 antigen by Phase, 2017
Figure 9: Number of CAR-T Clinical Trials & Completion Year, 2017
Figure 10:CAR T-cell Companies and Technologies, 2017

Table 1: CARs Generations-Associated Target Antigens and Indications
Table 2: CAR-T Cells Therapy - Company Collaborations and Deal Year, 2017
Table 3: CAR-T Cells Therapy - University Collaborations and Deal Year, 2017
Table 4: CAR-T Cells Therapy collaboration Deals and Values, 2017
Table 5: Companies CAR-T Investment for future developments, 2017
Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2017
Table 7:Companies open for licensing and collaborations, 2017
Table 8:Number of Products under Development, 2017
Table 9:Number of Products under Development by Companies, 2017
Table 10:Number of Products under Development by Indication, 2017
Table 11:Number of Products Targeting CD19 Antigen, 2017
Table 12:Number of Products Targeting Other Antigens, 2017
Table 13: Number of CAR-T Ongoing Clinical Trials & Completion Year, 2017
Table 14:CAR T-cell Companies and Technologies, 2017

Figure 1: Companies Collaborations vs. Financial year, 2017
Figure 2: Number of Companies Collaborations, 2017
Figure 3: Collaborations and Upfront Deal Values (In million, $), 2017
Figure 4: Number of Products under Development, 2017
Figure 5: Number of Products under Development by Companies, 2017
Figure 6: Number of Products under Development by Indication, 2017
Figure 7: CAR-T cell Targeted Antigens (%), 2017
Figure 8: Number of Products Targeting CD19 antigen by Phase, 2017
Figure 9: Number of CAR-T Clinical Trials & Completion Year, 2017
Figure 10:CAR T-cell Companies and Technologies, 2017

Table 1: CARs Generations-Associated Target Antigens and Indications
Table 2: CAR-T Cells Therapy - Company Collaborations and Deal Year, 2017
Table 3: CAR-T Cells Therapy - University Collaborations and Deal Year, 2017
Table 4: CAR-T Cells Therapy collaboration Deals and Values, 2017
Table 5: Companies CAR-T Investment for future developments, 2017
Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2017
Table 7:Companies open for licensing and collaborations, 2017
Table 8:Number of Products under Development, 2017
Table 9:Number of Products under Development by Companies, 2017
Table 10:Number of Products under Development by Indication, 2017
Table 11:Number of Products Targeting CD19 Antigen, 2017
Table 12:Number of Products Targeting Other Antigens, 2017
Table 13: Number of CAR-T Ongoing Clinical Trials & Completion Year, 2017
Table 14:CAR T-cell Companies and Technologies, 2017

Figure 1: Companies Collaborations vs. Financial year, 2017
Figure 2: Number of Companies Collaborations, 2017
Figure 3: Collaborations and Upfront Deal Values (In million, $), 2017
Figure 4: Number of Products under Development, 2017
Figure 5: Number of Products under Development by Companies, 2017
Figure 6: Number of Products under Development by Indication, 2017
Figure 7: CAR-T cell Targeted Antigens (%), 2017
Figure 8: Number of Products Targeting CD19 antigen by Phase, 2017
Figure 9: Number of CAR-T Clinical Trials & Completion Year, 2017
Figure 10:CAR T-cell Companies and Technologies, 2017

Table 1: CARs Generations-Associated Target Antigens and Indications
Table 2: CAR-T Cells Therapy - Company Collaborations and Deal Year, 2017
Table 3: CAR-T Cells Therapy - University Collaborations and Deal Year, 2017
Table 4: CAR-T Cells Therapy collaboration Deals and Values, 2017
Table 5: Companies CAR-T Investment for future developments, 2017
Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2017
Table 7:Companies open for licensing and collaborations, 2017
Table 8:Number of Products under Development, 2017
Table 9:Number of Products under Development by Companies, 2017
Table 10:Number of Products under Development by Indication, 2017
Table 11:Number of Products Targeting CD19 Antigen, 2017
Table 12:Number of Products Targeting Other Antigens, 2017
Table 13: Number of CAR-T Ongoing Clinical Trials & Completion Year, 2017
Table 14:CAR T-cell Companies and Technologies, 2017

Figure 1: Companies Collaborations vs. Financial year, 2017
Figure 2: Number of Companies Collaborations, 2017
Figure 3: Collaborations and Upfront Deal Values (In million, $), 2017
Figure 4: Number of Products under Development, 2017
Figure 5: Number of Products under Development by Companies, 2017
Figure 6: Number of Products under Development by Indication, 2017
Figure 7: CAR-T cell Targeted Antigens (%), 2017
Figure 8: Number of Products Targeting CD19 antigen by Phase, 2017
Figure 9: Number of CAR-T Clinical Trials & Completion Year, 2017
Figure 10:CAR T-cell Companies and Technologies, 2017

Table 1: CARs Generations-Associated Target Antigens and Indications
Table 2: CAR-T Cells Therapy - Company Collaborations and Deal Year, 2017
Table 3: CAR-T Cells Therapy - University Collaborations and Deal Year, 2017
Table 4: CAR-T Cells Therapy collaboration Deals and Values, 2017
Table 5: Companies CAR-T Investment for future developments, 2017
Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2017
Table 7:Companies open for licensing and collaborations, 2017
Table 8:Number of Products under Development, 2017
Table 9:Number of Products under Development by Companies, 2017
Table 10:Number of Products under Development by Indication, 2017
Table 11:Number of Products Targeting CD19 Antigen, 2017
Table 12:Number of Products Targeting Other Antigens, 2017
Table 13: Number of CAR-T Ongoing Clinical Trials & Completion Year, 2017
Table 14:CAR T-cell Companies and Technologies, 2017

Figure 1: Companies Collaborations vs. Financial year, 2017
Figure 2: Number of Companies Collaborations, 2017
Figure 3: Collaborations and Upfront Deal Values (In million, $), 2017
Figure 4: Number of Products under Development, 2017
Figure 5: Number of Products under Development by Companies, 2017
Figure 6: Number of Products under Development by Indication, 2017
Figure 7: CAR-T cell Targeted Antigens (%), 2017
Figure 8: Number of Products Targeting CD19 antigen by Phase, 2017
Figure 9: Number of CAR-T Clinical Trials & Completion Year, 2017
Figure 10:CAR T-cell Companies and Technologies, 2017

Table 1: CARs Generations-Associated Target Antigens and Indications
Table 2: CAR-T Cells Therapy - Company Collaborations and Deal Year, 2017
Table 3: CAR-T Cells Therapy - University Collaborations and Deal Year, 2017
Table 4: CAR-T Cells Therapy collaboration Deals and Values, 2017
Table 5: Companies CAR-T Investment for future developments, 2017
Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2017
Table 7:Companies open for licensing and collaborations, 2017
Table 8:Number of Products under Development, 2017
Table 9:Number of Products under Development by Companies, 2017
Table 10:Number of Products under Development by Indication, 2017
Table 11:Number of Products Targeting CD19 Antigen, 2017
Table 12:Number of Products Targeting Other Antigens, 2017
Table 13: Number of CAR-T Ongoing Clinical Trials & Completion Year, 2017
Table 14:CAR T-cell Companies and Technologies, 2017

Figure 1: Companies Collaborations vs. Financial year, 2017
Figure 2: Number of Companies Collaborations, 2017
Figure 3: Collaborations and Upfront Deal Values (In million, $), 2017
Figure 4: Number of Products under Development, 2017
Figure 5: Number of Products under Development by Companies, 2017
Figure 6: Number of Products under Development by Indication, 2017
Figure 7: CAR-T cell Targeted Antigens (%), 2017
Figure 8: Number of Products Targeting CD19 antigen by Phase, 2017
Figure 9: Number of CAR-T Clinical Trials & Completion Year, 2017
Figure 10:CAR T-cell Companies and Technologies, 2017

Table 1: CARs Generations-Associated Target Antigens and Indications
Table 2: CAR-T Cells Therapy - Company Collaborations and Deal Year, 2017
Table 3: CAR-T Cells Therapy - University Collaborations and Deal Year, 2017
Table 4: CAR-T Cells Therapy collaboration Deals and Values, 2017
Table 5: Companies CAR-T Investment for future developments, 2017
Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2017
Table 7:Companies open for licensing and collaborations, 2017
Table 8:Number of Products under Development, 2017
Table 9:Number of Products under Development by Companies, 2017
Table 10:Number of Products under Development by Indication, 2017
Table 11:Number of Products Targeting CD19 Antigen, 2017
Table 12:Number of Products Targeting Other Antigens, 2017
Table 13: Number of CAR-T Ongoing Clinical Trials & Completion Year, 2017
Table 14:CAR T-cell Companies and Technologies, 2017

Figure 1: Companies Collaborations vs. Financial year, 2017
Figure 2: Number of Companies Collaborations, 2017
Figure 3: Collaborations and Upfront Deal Values (In million, $), 2017
Figure 4: Number of Products under Development, 2017
Figure 5: Number of Products under Development by Companies, 2017
Figure 6: Number of Products under Development by Indication, 2017
Figure 7: CAR-T cell Targeted Antigens (%), 2017
Figure 8: Number of Products Targeting CD19 antigen by Phase, 2017
Figure 9: Number of CAR-T Clinical Trials & Completion Year, 2017
Figure 10:CAR T-cell Companies and Technologies, 2017

Table 1: CARs Generations-Associated Target Antigens and Indications
Table 2: CAR-T Cells Therapy - Company Collaborations and Deal Year, 2017
Table 3: CAR-T Cells Therapy - University Collaborations and Deal Year, 2017
Table 4: CAR-T Cells Therapy collaboration Deals and Values, 2017
Table 5: Companies CAR-T Investment for future developments, 2017
Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2017
Table 7:Companies open for licensing and collaborations, 2017
Table 8:Number of Products under Development, 2017
Table 9:Number of Products under Development by Companies, 2017
Table 10:Number of Products under Development by Indication, 2017
Table 11:Number of Products Targeting CD19 Antigen, 2017
Table 12:Number of Products Targeting Other Antigens, 2017
Table 13: Number of CAR-T Ongoing Clinical Trials & Completion Year, 2017
Table 14:CAR T-cell Companies and Technologies, 2017

Figure 1: Companies Collaborations vs. Financial year, 2017
Figure 2: Number of Companies Collaborations, 2017
Figure 3: Collaborations and Upfront Deal Values (In million, $), 2017
Figure 4: Number of Products under Development, 2017
Figure 5: Number of Products under Development by Companies, 2017
Figure 6: Number of Products under Development by Indication, 2017
Figure 7: CAR-T cell Targeted Antigens (%), 2017
Figure 8: Number of Products Targeting CD19 antigen by Phase, 2017
Figure 9: Number of CAR-T Clinical Trials & Completion Year, 2017
Figure 10:CAR T-cell Companies and Technologies, 2017

Table 1: CARs Generations-Associated Target Antigens and Indications
Table 2: CAR-T Cells Therapy - Company Collaborations and Deal Year, 2017
Table 3: CAR-T Cells Therapy - University Collaborations and Deal Year, 2017
Table 4: CAR-T Cells Therapy collaboration Deals and Values, 2017
Table 5: Companies CAR-T Investment for future developments, 2017
Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2017
Table 7:Companies open for licensing and collaborations, 2017
Table 8:Number of Products under Development, 2017
Table 9:Number of Products under Development by Companies, 2017
Table 10:Number of Products under Development by Indication, 2017
Table 11:Number of Products Targeting CD19 Antigen, 2017
Table 12:Number of Products Targeting Other Antigens, 2017
Table 13: Number of CAR-T Ongoing Clinical Trials & Completion Year, 2017
Table 14:CAR T-cell Companies and Technologies, 2017

Figure 1: Companies Collaborations vs. Financial year, 2017
Figure 2: Number of Companies Collaborations, 2017
Figure 3: Collaborations and Upfront Deal Values (In million, $), 2017
Figure 4: Number of Products under Development, 2017
Figure 5: Number of Products under Development by Companies, 2017
Figure 6: Number of Products under Development by Indication, 2017
Figure 7: CAR-T cell Targeted Antigens (%), 2017
Figure 8: Number of Products Targeting CD19 antigen by Phase, 2017
Figure 9: Number of CAR-T Clinical Trials & Completion Year, 2017
Figure 10:CAR T-cell Companies and Technologies, 2017

Table 1: CARs Generations-Associated Target Antigens and Indications
Table 2: CAR-T Cells Therapy - Company Collaborations and Deal Year, 2017
Table 3: CAR-T Cells Therapy - University Collaborations and Deal Year, 2017
Table 4: CAR-T Cells Therapy collaboration Deals and Values, 2017
Table 5: Companies CAR-T Investment for future developments, 2017
Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2017
Table 7:Companies open for licensing and collaborations, 2017
Table 8:Number of Products under Development, 2017
Table 9:Number of Products under Development by Companies, 2017
Table 10:Number of Products under Development by Indication, 2017
Table 11:Number of Products Targeting CD19 Antigen, 2017
Table 12:Number of Products Targeting Other Antigens, 2017
Table 13: Number of CAR-T Ongoing Clinical Trials & Completion Year, 2017
Table 14:CAR T-cell Companies and Technologies, 2017

Figure 1: Companies Collaborations vs. Financial year, 2017
Figure 2: Number of Companies Collaborations, 2017
Figure 3: Collaborations and Upfront Deal Values (In million, $), 2017
Figure 4: Number of Products under Development, 2017
Figure 5: Number of Products under Development by Companies, 2017
Figure 6: Number of Products under Development by Indication, 2017
Figure 7: CAR-T cell Targeted Antigens (%), 2017
Figure 8: Number of Products Targeting CD19 antigen by Phase, 2017
Figure 9: Number of CAR-T Clinical Trials & Completion Year, 2017
Figure 10:CAR T-cell Companies and Technologies, 2017

Table 1: CARs Generations-Associated Target Antigens and Indications
Table 2: CAR-T Cells Therapy - Company Collaborations and Deal Year, 2017
Table 3: CAR-T Cells Therapy - University Collaborations and Deal Year, 2017
Table 4: CAR-T Cells Therapy collaboration Deals and Values, 2017
Table 5: Companies CAR-T Investment for future developments, 2017
Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2017
Table 7:Companies open for licensing and collaborations, 2017
Table 8:Number of Products under Development, 2017
Table 9:Number of Products under Development by Companies, 2017
Table 10:Number of Products under Development by Indication, 2017
Table 11:Number of Products Targeting CD19 Antigen, 2017
Table 12:Number of Products Targeting Other Antigens, 2017
Table 13: Number of CAR-T Ongoing Clinical Trials & Completion Year, 2017
Table 14:CAR T-cell Companies and Technologies, 2017

Figure 1: Companies Collaborations vs. Financial year, 2017
Figure 2: Number of Companies Collaborations, 2017
Figure 3: Collaborations and Upfront Deal Values (In million, $), 2017
Figure 4: Number of Products under Development, 2017
Figure 5: Number of Products under Development by Companies, 2017
Figure 6: Number of Products under Development by Indication, 2017
Figure 7: CAR-T cell Targeted Antigens (%), 2017
Figure 8: Number of Products Targeting CD19 antigen by Phase, 2017
Figure 9: Number of CAR-T Clinical Trials & Completion Year, 2017
Figure 10:CAR T-cell Companies and Technologies, 2017

Table 1: CARs Generations-Associated Target Antigens and Indications
Table 2: CAR-T Cells Therapy - Company Collaborations and Deal Year, 2017
Table 3: CAR-T Cells Therapy - University Collaborations and Deal Year, 2017
Table 4: CAR-T Cells Therapy collaboration Deals and Values, 2017
Table 5: Companies CAR-T Investment for future developments, 2017
Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2017
Table 7:Companies open for licensing and collaborations, 2017
Table 8:Number of Products under Development, 2017
Table 9:Number of Products under Development by Companies, 2017
Table 10:Number of Products under Development by Indication, 2017
Table 11:Number of Products Targeting CD19 Antigen, 2017
Table 12:Number of Products Targeting Other Antigens, 2017
Table 13: Number of CAR-T Ongoing Clinical Trials & Completion Year, 2017
Table 14:CAR T-cell Companies and Technologies, 2017

Figure 1: Companies Collaborations vs. Financial year, 2017
Figure 2: Number of Companies Collaborations, 2017
Figure 3: Collaborations and Upfront Deal Values (In million, $), 2017
Figure 4: Number of Products under Development, 2017
Figure 5: Number of Products under Development by Companies, 2017
Figure 6: Number of Products under Development by Indication, 2017
Figure 7: CAR-T cell Targeted Antigens (%), 2017
Figure 8: Number of Products Targeting CD19 antigen by Phase, 2017
Figure 9: Number of CAR-T Clinical Trials & Completion Year, 2017
Figure 10:CAR T-cell Companies and Technologies, 2017

Table 1: CARs Generations-Associated Target Antigens and Indications
Table 2: CAR-T Cells Therapy - Company Collaborations and Deal Year, 2017
Table 3: CAR-T Cells Therapy - University Collaborations and Deal Year, 2017
Table 4: CAR-T Cells Therapy collaboration Deals and Values, 2017
Table 5: Companies CAR-T Investment for future developments, 2017
Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2017
Table 7:Companies open for licensing and collaborations, 2017
Table 8:Number of Products under Development, 2017
Table 9:Number of Products under Development by Companies, 2017
Table 10:Number of Products under Development by Indication, 2017
Table 11:Number of Products Targeting CD19 Antigen, 2017
Table 12:Number of Products Targeting Other Antigens, 2017
Table 13: Number of CAR-T Ongoing Clinical Trials & Completion Year, 2017
Table 14:CAR T-cell Companies and Technologies, 2017

Figure 1: Companies Collaborations vs. Financial year, 2017
Figure 2: Number of Companies Collaborations, 2017
Figure 3: Collaborations and Upfront Deal Values (In million, $), 2017
Figure 4: Number of Products under Development, 2017
Figure 5: Number of Products under Development by Companies, 2017
Figure 6: Number of Products under Development by Indication, 2017
Figure 7: CAR-T cell Targeted Antigens (%), 2017
Figure 8: Number of Products Targeting CD19 antigen by Phase, 2017
Figure 9: Number of CAR-T Clinical Trials & Completion Year, 2017
Figure 10:CAR T-cell Companies and Technologies, 2017

Table 1: CARs Generations-Associated Target Antigens and Indications
Table 2: CAR-T Cells Therapy - Company Collaborations and Deal Year, 2017
Table 3: CAR-T Cells Therapy - University Collaborations and Deal Year, 2017
Table 4: CAR-T Cells Therapy collaboration Deals and Values, 2017
Table 5: Companies CAR-T Investment for future developments, 2017
Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2017
Table 7:Companies open for licensing and collaborations, 2017
Table 8:Number of Products under Development, 2017
Table 9:Number of Products under Development by Companies, 2017
Table 10:Number of Products under Development by Indication, 2017
Table 11:Number of Products Targeting CD19 Antigen, 2017
Table 12:Number of Products Targeting Other Antigens, 2017
Table 13: Number of CAR-T Ongoing Clinical Trials & Completion Year, 2017
Table 14:CAR T-cell Companies and Technologies, 2017

Figure 1: Companies Collaborations vs. Financial year, 2017
Figure 2: Number of Companies Collaborations, 2017
Figure 3: Collaborations and Upfront Deal Values (In million, $), 2017
Figure 4: Number of Products under Development, 2017
Figure 5: Number of Products under Development by Companies, 2017
Figure 6: Number of Products under Development by Indication, 2017
Figure 7: CAR-T cell Targeted Antigens (%), 2017
Figure 8: Number of Products Targeting CD19 antigen by Phase, 2017
Figure 9: Number of CAR-T Clinical Trials & Completion Year, 2017
Figure 10:CAR T-cell Companies and Technologies, 2017

Table 1: CARs Generations-Associated Target Antigens and Indications
Table 2: CAR-T Cells Therapy - Company Collaborations and Deal Year, 2017
Table 3: CAR-T Cells Therapy - University Collaborations and Deal Year, 2017
Table 4: CAR-T Cells Therapy collaboration Deals and Values, 2017
Table 5: Companies CAR-T Investment for future developments, 2017
Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2017
Table 7:Companies open for licensing and collaborations, 2017
Table 8:Number of Products under Development, 2017
Table 9:Number of Products under Development by Companies, 2017
Table 10:Number of Products under Development by Indication, 2017
Table 11:Number of Products Targeting CD19 Antigen, 2017
Table 12:Number of Products Targeting Other Antigens, 2017
Table 13: Number of CAR-T Ongoing Clinical Trials & Completion Year, 2017
Table 14:CAR T-cell Companies and Technologies, 2017

Figure 1: Companies Collaborations vs. Financial year, 2017
Figure 2: Number of Companies Collaborations, 2017
Figure 3: Collaborations and Upfront Deal Values (In million, $), 2017
Figure 4: Number of Products under Development, 2017
Figure 5: Number of Products under Development by Companies, 2017
Figure 6: Number of Products under Development by Indication, 2017
Figure 7: CAR-T cell Targeted Antigens (%), 2017
Figure 8: Number of Products Targeting CD19 antigen by Phase, 2017
Figure 9: Number of CAR-T Clinical Trials & Completion Year, 2017
Figure 10:CAR T-cell Companies and Technologies, 2017

Key Companies
Speak to Analyst
Name*  
Email ID*  
Mobile*  
Company*  
Country*  
Zip Code*  
Specific Filed of Interest*  
X

Speak to Analyst

+1(919)321-6187

Related Reports

Contact Us

Phone

India: +91-11-45689769, +91-9650213330

Email

info@delveinsight.com

Address

New Delhi-110075, India

Address

304 S. Jones Blvd #2432, Las Vegas NV 89107

Phone

Outside India: +1(919)321-6187

Latest Tweets

Copyright © 2018 Delveinsight.